var title_f31_35_32304="Stool sample 7 with answer";
var content_f31_35_32304=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F55444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F55444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Giardia lamblia cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chlorazol black E stain of stool (x1000) shows the cyst of Giardia lamblia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_35_32304=[""].join("\n");
var outline_f31_35_32304=null;
var title_f31_35_32305="Dactylitis in psoratic juvenile idiopathic arthritis";
var content_f31_35_32305=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F79540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F79540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 600px\">",
"   <div class=\"ttl\">",
"    Dactylitis in psoratic juvenile idiopathic arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 580px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dactylitis in psJIA. Note sausage shape of the second and fourth toes (A) and fusiform swelling of forefinger and thumb (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_35_32305=[""].join("\n");
var outline_f31_35_32305=null;
var title_f31_35_32306="Patient information: Aortic regurgitation in adults (The Basics)";
var content_f31_35_32306=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/87672\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/35/34354\">",
"         Transthoracic echocardiogram (echo)",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/63/7154\">",
"          Person having an ECG",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/37/16980\">",
"           Cardiac catheterization",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?34/53/35667\">",
"         Patient information: Cardiac catheterization (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/51/25395\">",
"         Patient information: ECG and stress test (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/13/24787\">",
"         Patient information: Echocardiogram (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/42/36514\">",
"         Patient information: Heart murmurs (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?25/11/25778\">",
"         Patient information: Marfan syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/23/11635\">",
"         Patient information: Prosthetic valves (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Aortic regurgitation in adults (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H19548825\">",
"      <span class=\"h1\">",
"       What is aortic regurgitation?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Aortic regurgitation is a condition in which 1 of the valves in the heart, called the aortic valve, leaks. Doctors call this condition &ldquo;AR&rdquo; for short.",
"     </p>",
"     <p>",
"      When the heart valves work normally, they keep blood flowing in only 1 direction. The valves work like swinging doors that open only 1 way &ndash; they let blood out, but not back in. Normally, little or no blood is able to leak backward. But if the valves are not working properly, blood can go back in the direction it came from.",
"     </p>",
"     <p>",
"      The aortic valve normally keeps blood flowing from the left ventricle to the aorta (the large blood vessel that carries blood to the body). When the aortic valve leaks, it lets blood flow back into the left ventricle . Over time, this can lead to problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19548840\">",
"      <span class=\"h1\">",
"       What causes aortic regurgitation?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In general, AR is caused by either:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A diseased or damaged aortic valve",
"       </li>",
"       <li>",
"        Widening of the first part of the aorta (the part that surrounds the aortic valve)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19548855\">",
"      <span class=\"h1\">",
"       What are the symptoms of aortic regurgitation?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Early on, most people have no symptoms. They find out they have AR when their doctor or nurse hears a heart murmur on a routine exam. A heart murmur is an extra sound in the heartbeat that doctors or nurses hear when they listen to the heart with a stethoscope.",
"     </p>",
"     <p>",
"      When AR causes symptoms, they can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Heart palpitations, which feel like the heart is pounding, beating hard or fast, or skipping beats. People might notice this more when they lie down or lie on their left side.",
"       </li>",
"       <li>",
"        Chest pain",
"       </li>",
"       <li>",
"        Trouble breathing",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19548874\">",
"      <span class=\"h1\">",
"       Is there a test for aortic regurgitation?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will ask about your symptoms, do an exam, and order 1 or more tests. The test done most often to check for AR is an echocardiogram (also called an &ldquo;echo&rdquo;). This test uses sound waves to create a picture of the heart as it beats. It shows the size of the heart chambers, how well the heart pumps, and how well the heart valves work (",
"      <a class=\"graphic graphic_figure graphicRef77971 \" href=\"mobipreview.htm?33/35/34354\">",
"       figure 1",
"      </a>",
"      ). Your doctor might repeat this test over time to check whether your condition changes.",
"     </p>",
"     <p>",
"      You might have a test called an electrocardiogram (also called an &ldquo;ECG&rdquo; or &ldquo;EKG&rdquo;). This test measures the electrical activity in your heart (",
"      <a class=\"graphic graphic_figure graphicRef53145 \" href=\"mobipreview.htm?6/63/7154\">",
"       figure 2",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      To get more information about your heart, your doctor might order a test called cardiac catheterization (also called &ldquo;cardiac cath&rdquo;). During this procedure, a doctor puts a thin tube into a blood vessel in your leg and moves it up to your heart (",
"      <a class=\"graphic graphic_figure graphicRef77943 \" href=\"mobipreview.htm?16/37/16980\">",
"       figure 3",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Some people with aortic regurgitation will also have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A chest X-ray &ndash; This can show the size and shape of your heart and aorta.",
"       </li>",
"       <li>",
"        An imaging test, such as an MRI &ndash; This can show more detailed information about the size and shape of your heart and aorta.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19548940\">",
"      <span class=\"h1\">",
"       How is aortic regurgitation treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on your symptoms and how severe they are, and what&rsquo;s causing your AR. If your AR is mild or you have no symptoms, you might not need treatment right away. But your doctor will monitor your symptoms to see if and when they get worse.",
"     </p>",
"     <p>",
"      The main treatment for AR that is severe or causes symptoms is surgery to replace the aortic valve. During surgery, the doctor will remove the diseased valve and replace it with a valve that works normally. In some cases, the doctor will also fix a widened or torn part of the aorta during surgery.",
"     </p>",
"     <p>",
"      Other treatment depends on a person&rsquo;s individual situation. It might include heart medicines or treatment for high blood pressure.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19548955\">",
"      <span class=\"h1\">",
"       Can I play sports?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends on your AR and symptoms, the size of your aorta, and your other conditions. You and your doctor should discuss the level of physical activity that is right for you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19548970\">",
"      <span class=\"h1\">",
"       Do I need to take antibiotics before I go to the dentist?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In general, no. In the past, doctors recommended that people with AR take antibiotics before going to the dentist or having certain medical or dental procedures. But now, only people with certain heart conditions need antibiotics before going to the dentist or having a procedure. Most people with AR do not need antibiotics for those times.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19548985\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to get pregnant, talk with your doctor before you start trying. He or she might recommend treatment for your AR before you get pregnant. He or she will also make sure that any medicines you take are safe to take during pregnancy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19549000\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/42/36514?source=see_link\">",
"       Patient information: Heart murmurs (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/23/11635?source=see_link\">",
"       Patient information: Prosthetic valves (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/51/25395?source=see_link\">",
"       Patient information: ECG and stress test (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/13/24787?source=see_link\">",
"       Patient information: Echocardiogram (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/53/35667?source=see_link\">",
"       Patient information: Cardiac catheterization (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/11/25778?source=see_link\">",
"       Patient information: Marfan syndrome (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?31/35/32306?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 87672 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-2FACFC3B1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_35_32306=[""].join("\n");
var outline_f31_35_32306=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19548825\">",
"      What is aortic regurgitation?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19548840\">",
"      What causes aortic regurgitation?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19548855\">",
"      What are the symptoms of aortic regurgitation?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19548874\">",
"      Is there a test for aortic regurgitation?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19548940\">",
"      How is aortic regurgitation treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19548955\">",
"      Can I play sports?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19548970\">",
"      Do I need to take antibiotics before I go to the dentist?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19548985\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19549000\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/87672\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/35/34354\">",
"      Transthoracic echocardiogram (echo)",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/63/7154\">",
"       Person having an ECG",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/37/16980\">",
"        Cardiac catheterization",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/53/35667?source=related_link\">",
"      Patient information: Cardiac catheterization (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/51/25395?source=related_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/42/36514?source=related_link\">",
"      Patient information: Heart murmurs (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/11/25778?source=related_link\">",
"      Patient information: Marfan syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/23/11635?source=related_link\">",
"      Patient information: Prosthetic valves (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_35_32307="Kaposis sarcoma eyelid";
var content_f31_35_32307=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F80323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F80323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Kaposi's sarcoma eyelid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 407px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     With permission from Slomovits, TL (Ed), Basic and clinical science courses section, American Academy of Ophthalmology, San Francisco 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_35_32307=[""].join("\n");
var outline_f31_35_32307=null;
var title_f31_35_32308="Potassium citrate (tablet): Patient drug information";
var content_f31_35_32308=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Potassium citrate (tablet): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/59/7092?source=see_link\">",
"     see \"Potassium citrate (tablet): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F211872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Urocit&reg;-K",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F211873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Urocit&reg;-K",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691398",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to raise the urine's pH.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691689",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat acid problems in the blood.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691468",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop kidney stones.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702768",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to potassium citrate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703218",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: High blood sugar (diabetes), fluid loss, high potassium levels, bowel block, very bad kidney disease, or untreated Addison's disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701072",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are on a low-salt or salt-free diet.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697284",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney stones, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696686",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid salt substitutes that have potassium, potassium-sparing diuretics, or potassium products.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High potassium level. Signs include feeling weak, lightheaded, dizzy, feel like passing out, or have numbness or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699070",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of high potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11835 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.211.0.116-7A2182FD3F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_35_32308=[""].join("\n");
var outline_f31_35_32308=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211872\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211873\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012635\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012634\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012639\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012640\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012642\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012637\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012638\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012643\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012644\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?6/59/7092?source=related_link\">",
"      Potassium citrate (tablet): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_35_32309="Phenelzine: Patient drug information";
var content_f31_35_32309=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Phenelzine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/42/20135?source=see_link\">",
"     see \"Phenelzine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F208843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nardil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F208844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nardil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Children and teens who take this drug may be at a greater risk of having thoughts or actions of suicide. Adults may also be at risk. The risk may be greater in people who have had these thoughts or actions in the past. Watch people who take this drug closely. Call the doctor right away if signs like low mood (depression), nervousness, restlessness, grouchiness, panic attacks, or changes in mood or actions are new or worse. Call the doctor right away if any thoughts or actions of suicide occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691809",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression). It is most often given after other drugs have failed to help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702723",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to phenelzine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Very bad kidney disease, liver disease, pheochromocytoma, very high blood pressure, or a weak heart.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701242",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking any of these drugs: Citalopram, fluvoxamine, paroxetine, or sertraline. Do not use within 2 weeks of other antidepressants.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701004",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stop fluoxetine for at least 5 weeks before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701346",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you cannot follow the diet needed when taking this drug. See How Is This Drug Best Taken? for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696931",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use OTC drugs that have dextromethorphan or pseudoephedrine. They may cause very high blood pressure when used with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid use of caffeine (for example, tea, coffee, cola) and chocolate.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698132",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698632",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Confusion; very nervous; anger with sweating, shivering, stiffness, or shaking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694864",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow a diet plan. Some foods and drinks taken with this drug may cause very risky effects such as sudden high blood pressure. To avoid these problems, get a list of foods to avoid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694534",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid eating foods like aged cheeses and meats, soy sauce, soy beans, Miso soup, Italian green beans (fava beans), snowpea or broad bean pods, sauerkraut, kimchee, yeast extracts (Marmite), red or white wine, and beer including alcohol-free beer. Very bad side effects may happen. Ask your doctor for a list of foods to avoid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695129",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If this drug is stopped, follow diet for at least 2 more weeks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10970 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-2FACFC3B1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_35_32309=[""].join("\n");
var outline_f31_35_32309=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208843\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208844\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020915\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020917\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020916\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020921\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020922\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020924\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020919\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020920\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020925\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020926\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/42/20135?source=related_link\">",
"      Phenelzine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_35_32310="Left-sided heart failure - low power";
var content_f31_35_32310=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Liver biospy from a patient with left-sided heart failure (low power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pericentral areas demonstrate a loss of hepatocytes and replacement by red blood cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_35_32310=[""].join("\n");
var outline_f31_35_32310=null;
var title_f31_35_32311="Thioridazine: Drug information";
var content_f31_35_32311=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Thioridazine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/36/19013?source=see_link\">",
"    see \"Thioridazine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/11/7350?source=see_link\">",
"    see \"Thioridazine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F227120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antipsychotic Agent, Typical, Phenothiazine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F227082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Schizophrenia/psychosis:",
"     </b>",
"     Oral: Initial: 50-100 mg 3 times/day with gradual increments as needed and tolerated; maximum: 800 mg/day in 2-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Depressive disorders, dementia (unlabeled use):",
"     </b>",
"     Oral: Initial: 25 mg 3 times/day; maintenance dose: 20-200 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F227099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/11/7350?source=see_link\">",
"      see \"Thioridazine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Schizophrenia/psychosis (unlabeled use):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;2-12 years: Range: 0.5-3 mg/kg/day in 2-3 divided doses; usual: 1 mg/kg/day; maximum: 3 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Behavior problems (unlabeled use):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;2-12 years: Initial: 10 mg 2-3 times/day, increase gradually.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Severe psychoses (unlabeled use):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;2-12 years: Initial: 25 mg 2-3 times/day, increase gradually.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F227083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Behavioral symptoms associated with dementia (unlabeled use): Oral: Initial: 10-25 mg 1-2 times/day; increase at 4- to 7-day intervals by 10-25 mg/day; increase dose intervals (once daily, twice daily, etc) as necessary to control response or side effects. Maximum daily dose: 400 mg; gradual increases (titration) may prevent some side effects or decrease their severity.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F227084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not dialyzable (0% to 5%)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F227057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 10 mg, 25 mg, 50 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F227041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F227062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not take antacid within 2 hours of taking drug.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F227061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of schizophrenic patients who fail to respond adequately to treatment with other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those medications",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F227117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Behavior problems (children); severe psychoses (children); schizophrenia/psychoses (children); depressive disorders/dementia (children and adults); behavioral symptoms associated with dementia (elderly); psychosis/agitation related to Alzheimer's dementia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F227127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Thioridazine may be confused with thiothixene, Thorazine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Mellaril may be confused with Elavil, Mebaral&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F227118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension, orthostatic hypotension, peripheral edema, ECG changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: EPS (pseudoparkinsonism, akathisia, dystonias, tardive dyskinesia), dizziness, drowsiness, neuroleptic malignant syndrome (NMS), impairment of temperature regulation, lowering of seizure threshold",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Increased sensitivity to sun, rash, discoloration of skin (blue-gray)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Changes in menstrual cycle, libido (changes in), breast pain, galactorrhea, amenorrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, weight gain, nausea, vomiting, stomach pain, xerostomia, diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Difficulty in urination, ejaculatory disturbances, urinary retention, priapism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice, hepatotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Pigmentary retinopathy, blurred vision, cornea and lens changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasal congestion",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F227065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe CNS depression; severe hyper-/hypotensive heart disease; coma; in combination with other drugs that are known to prolong the QT",
"     <sub>",
"      c",
"     </sub>",
"     interval and/or CYP2D6 inhibitors; in patients with congenital long QT syndrome or a history of cardiac arrhythmias; concurrent use with medications that inhibit the metabolism of thioridazine (fluoxetine, paroxetine, fluvoxamine, propranolol, pindolol); patients known to have genetic defect leading to reduced levels of activity of CYP2D6",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F227045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Arrhythmias:",
"     <b>",
"      [U.S. Boxed Warning]: Has dose-related effects on ventricular repolarization leading to QT",
"      <sub>",
"       c",
"      </sub>",
"      prolongation, a potentially life-threatening effect.",
"     </b>",
"     Therefore, it should be reserved for patients with schizophrenia who have failed to respond to adequate levels of other antipsychotic drugs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems. Relative to other neuroleptics, thioridazine has a high potency of cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, pre-existing low WBC or history of drug-induced leuko-/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; use with caution in patients at risk of pneumonia (ie, Alzheimer's disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extrapyramidal symptoms (EPS): May cause extrapyramidal symptoms, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia. Risk of dystonia (and possibly other EPS) may be greater with increased doses, use of conventional antipsychotics, males, and younger patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperprolactinemia: Use associated with increased prolactin levels; clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic malignant syndrome (NMS): May be associated with NMS; monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: May cause pigmentary retinopathy, and lenticular and corneal deposits, particularly with prolonged therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: Highly sedating which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with severe cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo.",
"     </b>",
"     Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Thioridazine is not approved for the treatment of dementia-related psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with narrow-angle glaucoma; condition may be exacerbated by cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; condition may be exacerbated by cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Use with caution in patients with Parkinson's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antiemetic effects: May mask toxicity of other drugs or conditions (eg, intestinal obstruction, Reye's syndrome, brain tumor) due to antiemetic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Due to potential for QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation; use contraindicated with concomitant CYP2D6 inhibitors and/or concomitant use with other agents that prolong the QT",
"     <sub>",
"      c",
"     </sub>",
"     interval.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use; potent anticholinergic agent with potential to cause QT-interval prolongation. Use in patients with dementia is associated with an increased risk of mortality and cerebrovascular accidents; avoid antipsychotic use for behavioral problems associated with dementia unless alternative nonpharmacologic therapies have failed and patient may harm self or others. In addition, use may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F227115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (minor), CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C9 (weak), CYP2D6 (strong), CYP2E1 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F227050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Antipsychotic Agents (Phenothiazines) may enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). Specifically, this may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. Antidepressants (Serotonin Reuptake Inhibitor/Antagonist) may enhance the hypotensive effect of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antimalarial Agents: May increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): May diminish the therapeutic effect of Antipsychotics (Typical). Antipsychotics (Typical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist). Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson's agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.  Management: Initiate atomoxetine at a reduced dose (adult doses -- patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Antipsychotic Agents (Phenothiazines) may enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors: May decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Strong) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FluvoxaMINE: May increase the serum concentration of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moclobemide: May increase the serum concentration of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F227074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid kava kava, valerian, St John's wort, gotu kola (may increase CNS depression). Avoid dong quai, St John's wort (may also cause photosensitization).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F227053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12586216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Jaundice or hyper-/hyporeflexia have been reported in newborn infants following maternal use of phenothiazines. Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F12586217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Other phenothiazines are excreted in human milk; excretion of thioridazine is not known.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F227067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Thioridazine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $34.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $48.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $60.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $68.50",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F227055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline and periodic ECG; vital signs; serum potassium, lipid profile, fasting blood glucose and Hgb A",
"     <sub>",
"      1c",
"     </sub>",
"     ; BMI; mental status, abnormal involuntary movement scale (AIMS); periodic eye exam; do not initiate if QT",
"     <sub>",
"      c",
"     </sub>",
"     &gt;450 msec",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F227058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Toxic: &gt;1 mg/mL; lethal: 2-8 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F227068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aldazine (AU, NZ);",
"     </li>",
"     <li>",
"      Meleril (AR, CN, CO, PY, UY, VE);",
"     </li>",
"     <li>",
"      Mellerette (IT);",
"     </li>",
"     <li>",
"      Melleril (AE, AT, BE, BF, BG, BH, BJ, BR, CH, CI, CY, CZ, DE, DK, EE, EG, ES, ET, FR, GB, GH, GM, GN, GR, HN, ID, IE, IQ, IR, IT, JO, KE, KP, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, MX, NE, NG, NL, NO, OM, PE, PK, PT, QA, RU, SA, SC, SD, SE, SK, SL, SN, SY, TN, TR, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Mellerzin (TW);",
"     </li>",
"     <li>",
"      Melzin (TW);",
"     </li>",
"     <li>",
"      Orsanil (FI);",
"     </li>",
"     <li>",
"      Ridazin (IL, IN);",
"     </li>",
"     <li>",
"      Ridazine (CL, TH);",
"     </li>",
"     <li>",
"      Tensenol (CN);",
"     </li>",
"     <li>",
"      Thinin (TW);",
"     </li>",
"     <li>",
"      Thiomed (TH);",
"     </li>",
"     <li>",
"      Thioridazin (PL);",
"     </li>",
"     <li>",
"      Thioridazin prolongatum (PL);",
"     </li>",
"     <li>",
"      Thioril (IN);",
"     </li>",
"     <li>",
"      Thiosia (TH);",
"     </li>",
"     <li>",
"      Thiozine (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F227044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Thioridazine is a piperidine phenothiazine which blocks postsynaptic mesolimbic dopaminergic receptors in the brain; exhibits a strong alpha-adrenergic blocking effect and depresses the release of hypothalamic and hypophyseal hormones",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F227064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 4-5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 21-25 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: ~1 hour",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aman MG, Marks RE, Turbott SH, et al, &ldquo;Clinical Effects of Methylphenidate and Thioridazine in Intellectually Subaverage Children,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1991, 30(2):246-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/35/32311/abstract-text/2016229/pubmed\" id=\"2016229\" target=\"_blank\">",
"        2016229",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/35/32311/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Appell RA, Shield DE, and McGuire EJ, &ldquo;Thioridazine-Induced Priapism,&rdquo;",
"      <i>",
"       Br J Urol",
"      </i>",
"      , 1977, 49(2):160.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/35/32311/abstract-text/858035/pubmed\" id=\"858035\" target=\"_blank\">",
"        858035",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baker PB, Merigian KS, Roberts JR, et al, &ldquo;Hyperthermia, Hypertension, Hypertonia, and Coma in Massive Thioridazine Overdose,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1988, 6(4):346-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/35/32311/abstract-text/3390252/pubmed\" id=\"3390252\" target=\"_blank\">",
"        3390252",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buckley NA, Whyte IM, and Dawson AH, &ldquo;Cardiotoxicity More Common in Thioridazine Overdose Than With Other Neuroleptics,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1995, 33(3):199-204.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/35/32311/abstract-text/7760442/pubmed\" id=\"7760442\" target=\"_blank\">",
"        7760442",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burgess KR, Jefferis RW, and Stevenson IF, &ldquo;Fatal Thioridazine Cardiotoxicity,&rdquo;",
"      <i>",
"       Med J Aust",
"      </i>",
"      , 1979, 2(4):177-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cowen TD and Meythaler JM, &ldquo;Hypotensive Effects of Thioridazine in an Elderly Patient With Traumatic Brain Injury,&rdquo;",
"      <i>",
"       Brain Inj",
"      </i>",
"      , 1994, 8(8):735-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/35/32311/abstract-text/7849693/pubmed\" id=\"7849693\" target=\"_blank\">",
"        7849693",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gill SS, Bronskill SE, Normand SL, et al, &ldquo;Antipsychotic Drug Use and Mortality in Older Adults With Dementia,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2007, 146(11):775-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/35/32311/abstract-text/17548409/pubmed\" id=\"17548409\" target=\"_blank\">",
"        17548409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goss JB, &ldquo;Concomitant Use of Thioridazine With Risperidone,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1995, 52(9):1012.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/35/32311/abstract-text/7543812/pubmed\" id=\"7543812\" target=\"_blank\">",
"        7543812",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lancelin F, Kraoul L, Flatischler N, et al, &ldquo;False-Positive Results in the Detection of Methadone in Urines of Patients Treated With Psychotropic Substances,&rdquo;",
"      <i>",
"       Clin Chem",
"      </i>",
"      , 2005, 51(11):2176-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/35/32311/abstract-text/16244295/pubmed\" id=\"16244295\" target=\"_blank\">",
"        16244295",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Long C, Crifasi J, and Maginn D, &ldquo;Interference of Thioridazine in Identification of Phencyclidine,&rdquo;",
"      <i>",
"       Clin Chem",
"      </i>",
"      , 1996, 42(11):1885-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/35/32311/abstract-text/8906100/pubmed\" id=\"8906100\" target=\"_blank\">",
"        8906100",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moore TA, &ldquo;Schizophrenia Treatment Guidelines in the United States,&rdquo;",
"      <i>",
"       Clin Schizophr Relat Psychoses",
"      </i>",
"      , 2011, 5(1):40-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/35/32311/abstract-text/21459738/pubmed\" id=\"21459738\" target=\"_blank\">",
"        21459738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oshika T, &ldquo;Ocular Adverse Effects of Neuropsychiatric Agents. Incidence and Management,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1995, 12(4):256-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/35/32311/abstract-text/7646824/pubmed\" id=\"7646824\" target=\"_blank\">",
"        7646824",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peabody CA, Warner MD, Whiteford HA, et al, &ldquo;Neuroleptics and the Elderly,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1987, 35(3):233-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/35/32311/abstract-text/2880887/pubmed\" id=\"2880887\" target=\"_blank\">",
"        2880887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rabins PV, Blacker D, Rovner BW, et al, &ldquo;American Psychiatric Association Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Second Edition,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(12 Suppl):5-56.  Available at file://psychiatryonline.org/guidelines.aspx",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/35/32311/abstract-text/18340692/pubmed\" id=\"18340692\" target=\"_blank\">",
"        18340692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Risse SC and Barnes R, &ldquo;Pharmacologic Treatment of Agitation Associated With Dementia,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1986, 34(5):368-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/35/32311/abstract-text/2870097/pubmed\" id=\"2870097\" target=\"_blank\">",
"        2870097",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saltz BL, Woerner MG, Kane JM, et al, &ldquo;Prospective Study of Tardive Dyskinesia Incidence in the Elderly,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1991, 266(17):2402-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/35/32311/abstract-text/1681122/pubmed\" id=\"1681122\" target=\"_blank\">",
"        1681122",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schneeweiss S, Setoguchi S, Brookhart A, et al, &ldquo;Risk of Death Associated With the Use of Conventional Versus Atypical Antipsychotic Drugs Among Elderly Patients,&rdquo;",
"      <i>",
"       CMAJ",
"      </i>",
"      , 2007, 176(5): 627-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/35/32311/abstract-text/17325327/pubmed\" id=\"17325327\" target=\"_blank\">",
"        17325327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seifert RD, &ldquo;Therapeutic Drug Monitoring: Psychotropic Drugs,&rdquo;",
"      <i>",
"       J Pharm Pract",
"      </i>",
"      , 1984, 6:403-16.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9991 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-200.215.4.194-785DB895A1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_35_32311=[""].join("\n");
var outline_f31_35_32311=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708963\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227120\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227082\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227099\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227083\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227084\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227057\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227041\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227062\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227061\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227117\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227127\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227118\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227065\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227045\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227115\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227050\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227074\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227053\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12586216\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12586217\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227067\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227055\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227058\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227068\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227044\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227064\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9991\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9991|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/36/19013?source=related_link\">",
"      Thioridazine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/11/7350?source=related_link\">",
"      Thioridazine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_35_32312="Epidemiology and laboratory diagnosis of parvovirus B19 infection";
var content_f31_35_32312=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and laboratory diagnosis of parvovirus B19 infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/35/32312/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/35/32312/contributors\">",
"     Jeanne A Jordan, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/35/32312/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/35/32312/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/35/32312/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/35/32312/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/35/32312/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/35/32312/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Parvoviridae family contains two subfamilies: Parvovirinae, which infect mammals and birds, and Densovirinae, which infect arthropods. The Parvovirinae subfamily has been subdivided into five genera: Erythrovirus, Dependovirus, Parvovirus, Amdovirus, and Bocavirus. The focus here will be limited to Erythrovirus genera, and mainly to human parvovirus B19 (B19 prototype strain); only brief coverage will be given to the less common genotype 2 (prototype strain: LaLi) and genotype 3 (prototype strain: V9) genera within this subfamily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are three genotypes (genotypes 1, 2 and 3) within the Erythrovirus genera. Genotype 1 (Prototype stain; Au) circulates worldwide, whereas genotypes 2 and 3 are geographically more restricted and found at lower prevalences. The nucleotide divergence is significantly greater when comparing genotype 1 to either genotypes 2 or 3 (&gt;11 percent), with slightly less divergence between genotypes 2 and 3 (~8 percent). Not surprisingly, the divergence at the amino acid level among the three genotypes is significantly less than that seen at the nucleotide level.",
"   </p>",
"   <p>",
"    Unless otherwise specified, B19 will be the strain referred to when describing the spectrum of disease manifestations, epidemiologic patterns and diagnostic testing related to Erythrovirus infections. Compared with genotype 1, much less has been published on the transmission and epidemiology of genotype 2 and genotype 3. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22377?source=see_link\">",
"     \"Clinical manifestations and pathogenesis of human parvovirus B19 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/1/31767?source=see_link\">",
"     \"Treatment and prevention of parvovirus B19 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One of the hallmarks of Erythroviruses is their extremely limited host range. Productive infections occur only in human erythroid precursor cells. B19 is directly cytotoxic to colony-forming units (CFU-E) and burst-forming units (BFU-E) of the erythroid series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    B19 is a relatively simple, small nonenveloped DNA virus consisting of a linear single-stranded 5.6 kb genome encoding for the following proteins:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two viral capsid proteins, VP1 (83 kDa) and VP2 (58 kDa) are expressed during productive infection; the smaller VP2 protein constitutes 95 percent of the capsid while the larger VP1 protein makes up only 5 percent.",
"     </li>",
"     <li>",
"      The nonstructural protein, NS1 (71 or 77 kDa), is involved in transregulation of its P6 promoter, and has helicase activity. It also plays a role in inducing cellular apoptosis in both permissive and non-permissive cell types [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    B19 is among the smallest of the DNA animal viruses, with a virion capsid diameter of between 18 to 26 nm. Both its small size and its lack of a lipid envelope make B19 extremely difficult to inactivate or remove from blood products. This is an important issue in the blood banking industry, because many individuals infected with B19 are asymptomatic, yet are circulating very high viral loads (10(9) to 10(12) viral",
"    <span class=\"nowrap\">",
"     particles/mL",
"    </span>",
"    of blood) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parvovirus B19 infection occurs worldwide. Cases can be sporadic or can occur in clustered outbreaks. The infection is easily transmitted from person to person via the respiratory route. In the United States, B19 infection occurs more frequently between late winter and early summer. Where reportable, communities have documented not only a seasonality to B19 infections, but also cycles of local epidemics with case numbers that can peak every four to 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The genetic variants of the Erythrovirus genera mentioned above, genotypes 2 and 3, have primarily been detected in Northern European countries (eg, Denmark, Finland, Sweden, and France), while they are uncommon in the United States. These genotypes are also identified among patients with underlying immune deficiencies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/11-15\">",
"     11-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parvovirus B19 infection is common throughout the world. The percentage of people with measurable levels of B19-specific IgG increases with increasing age, with most individuals becoming infected during their school years. During school outbreaks, 25 to 50 percent of students and 20 percent or more of susceptible staff may become infected. More than 70 percent of adults have measurable B19-specific IgG antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. When considering women as a separate group, approximately 30 to 40 percent of pregnant women lack measurable IgG to B19 and are therefore presumed to be susceptible to B19 infection, which then places their infant at risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Incubation period and infectivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infected patients are most contagious during the phase of active viral replication and viral shedding, which occurs approximately 5 to 10 days after the exposure. During this phase, patients can be asymptomatic or present with non-specific flu-like illness. It is not until the second phase of parvovirus infection that a person can present with specific symptoms or signs (eg, arthralgia, arthritis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an exanthem) of B19 infection. This is also the phase in which B19-specific antibody production and B19 antigen-antibody immune complex formations occur. Individuals are no longer infectious when exhibiting these clinical characteristics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three documented modes of transmitting B19:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory transmission is the most common way an individual acquires this virus. Although B19 is primarily associated with nonrespiratory symptoms, it is nevertheless transmitted through close person-to-person contact, fomites, and respiratory secretions",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      saliva [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/18\">",
"       18",
"      </a>",
"      ]. Young children are the main source of respiratory acquired B19. Therefore, individuals at highest risk for acquiring the virus include household contacts, daycare workers and those in a crowded environment.",
"      <br/>",
"      <br/>",
"      This scenario places pregnant women with young children at home at high risk of becoming infected. This can be problematic if she is not immune to the virus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/19-21\">",
"       19-21",
"      </a>",
"      ]. Healthcare workers may or may not be at increased risk of transmission depending upon the degree of contact that they have with infected patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/22-24\">",
"       22-24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vertical transmission can occur if a susceptible woman becomes infected during her pregnancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/25\">",
"       25",
"      </a>",
"      ]. The risk of a poor outcome for the fetus is greatest when the congenital infection occurs within the first 20 weeks of gestation.",
"     </li>",
"     <li>",
"      Hematogenous transmission can occur from administration of blood or blood products containing B19 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/26-31\">",
"       26-31",
"      </a>",
"      ]. Individuals requiring regular infusions of blood product(s) that are made from large plasma pools are at greatest risk for acquiring the virus compared to those individuals receiving single units [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/28,29\">",
"       28,29",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In contrast to B19 infections, PARV4 infections are most frequently detected in injection drug users, particularly those who are coinfected with HIV-1. One study demonstrated prevalent exposure to a novel human parvovirus (PARV4) among hemophiliacs and injection drug users. Serum from persons at risk showed frequent reactivity in ELISA testing using VP2 as an antigen, while uniform negativity was noted among adult control subjects at low risk of parenteral exposures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LABORATORY DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     B19 immune status",
"    </span>",
"    &nbsp;&mdash;&nbsp;The B19 immune status varies with acute infection, previous infection, and reactivation of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Acute infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of diagnostic testing for acute B19 infection will depend on the patient's immune status. In immunocompetent individuals, the preferred method is serologic testing to detect circulating B19-specific IgM and IgG antibodies (see",
"    <a class=\"local\" href=\"#H11\">",
"     'B19-specific assays'",
"    </a>",
"    below). However, in the immunosuppressed patient, or for congenital infections, nucleic acid amplification testing (NAAT) is recommended. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Nucleic acid detection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Analyzing sera for the presence of B19-specific IgM antibodies is a practical and common approach for diagnosing acute infection in the immunocompetent individual [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/33\">",
"     33",
"    </a>",
"    ]. Detectable levels of B19-specific IgM can be found within 7 to 10 days of virus exposure and remain measurable for several months before diminishing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/34\">",
"     34",
"    </a>",
"    ]. In some patients, B19-specific IgM antibodies can persist for six months or more. Therefore, the presence of these antibodies, especially at low titers, is suggestive but not conclusive proof of recent infection.",
"   </p>",
"   <p>",
"    Acute infection can also be diagnosed by demonstrating a fourfold or greater rise in serum B19-specific IgG antibody titers. However, since this procedure requires two separate time points for sample collection, it is considered impractical in most clinical situations. Today, most serology testing will include concurrent analyses for both B19-specific IgM and IgG antibodies from a single blood sample.",
"   </p>",
"   <p>",
"    NAAT is frequently used today to detect B19 DNA. At present, NAAT is considered the most sensitive approach for direct detection of virus within a specimen, and is the test of choice for diagnosing acute infection in the immunocompromised or immunosuppressed patient, including the fetus and neonate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Previous infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Previous infection is best confirmed by serologic testing that detects B19-specific IgG antibodies. Documenting previous infection, which infers immunity, is a common practice in obstetrics when the physician is concerned about the immune status of a pregnant woman who has a history of exposure to an individual infected with B19, especially if the contact is her own school-aged or younger children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Reactivation of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactivation of persistent infection occurs in immunocompetent and, more often, immunocompromised individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/35\">",
"     35",
"    </a>",
"    ]. These infections are confirmed by demonstrating the presence of the virus for a prolonged period; this is most often accomplished by NAAT to detect B19 DNA within a specimen. Individuals with persistent infection may also have measurable levels of B19-specific IgM antibodies over time if they are healthy enough to produce immunoglobulin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     B19-specific assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough serologic analysis of B19-specific antibody status should include testing for both IgM and IgG antibodies recognizing viral capsid antigen(s) (VP1",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    VP2). Many clinical laboratories complement B19 serology testing with NAAT to detect B19 DNA directly. Specifics on these assays are discussed below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     IgM antibody assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detecting B19-specific IgM antibodies to viral capsid antigen(s) is the cornerstone in determining whether immunocompetent individuals are actively infected. Several B19-specific IgM enzyme immunoassays (EIAs) are commercially available. However, the analytical parameters of these assays can, vary considerably both in sensitivity (70 to 100 percent) and specificity (76 to 100 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. In a study that was designed to compare correlations between B19 viral DNA loads and antibody responses to viral antigens VP1 and VP2, the anti-VP2 EIA (Biotrin, Ltd, Dublin, Ireland, recently acquired by Diasorin S.p.A., Saluggia, Italy) demonstrated significantly better sensitivity compared to the anti-VP1 immunofluorescence assay (91 versus 66 percent); both assays had good specificity (94 and 97 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    B19-specific IgM assay performance and thus its accuracy is greatly enhanced when the serologic method includes a step in its protocol to deplete or remove IgG antibodies from the serum sample [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/33,38\">",
"     33,38",
"    </a>",
"    ]. Because IgG antibodies are present in significantly higher concentrations than IgM antibodies, assays lacking this design are subject to higher rates of false negative results due to antibody competition. The mu capture format helps minimize false negative IgM results resulting in excellent sensitivity and specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/37,40,41\">",
"     37,40,41",
"    </a>",
"    ]. The presence of rheumatoid factor, anti-nuclear antibodies, and Epstein-Barr virus IgM in a specimen can also generate false positive IgM results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     IgG antibody assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several EIA kits are commercially available for B19-specific IgG analysis, many of which have excellent sensitivity and specificity. The different kits vary in their antigen composition: some contain recombinant VP2 alone, while others consist of a combination of VP1 and VP2 antigens. Kits containing conformational B19 antigens have improved performance over kits containing only linear B19 antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The choice of antigen(s) is critical when selecting a diagnostic serology assay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Commercial companies cannot rely on native virus as a source of antigen for their kits, since B19 isn't readily propagated in a tissue culture system. As a result, recombinant viral antigens are used. These antigens have been produced both in a prokaryotic expression vector (E. coli) and a eukaryotic expression system (Baculovirus) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. The viral antigens produced in the baculovirus system can self assemble into empty capsids as demonstrated by electron microscopy studies, and as such are more similar to native virions than the linear antigens produced in E. coli.",
"   </p>",
"   <p>",
"    Unlike NAAT, serology testing does not appear to suffer from recognition issues between genotypes 1, 2 and 3 as the level of divergence among the strains at the amino acid level is significantly less than that seen at the nucleotide level.",
"   </p>",
"   <p>",
"    In addition to serology tests that detect circulating antibodies to viral capsid proteins, other assays have been described that detect B19-specific IgM and IgG antibodies to the nonstructural protein NS1. Including these, in addition to detecting viral capsid proteins (VP1",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    VP2), can improve the accuracy of diagnosing acute B19 infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. However, NS1 specific serologic reagents are not yet commercially available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Nucleic acid detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detecting B19 DNA using NAAT is now routinely performed in many clinical laboratories, and has been shown to be much more sensitive than antigen-based detection systems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. Analyte-specific reagents are available from several manufacturers for detecting B19 DNA. Numerous PCR-based primer and probe sets have been described for detecting B19-specific DNA target(s). Most of these oligonucleotides were designed to detect genotype 1 DNA, but not genotypes 2 or 3, which can lead to failure in detecting non-genotype 1 erythrovirus infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/11,12,14,15\">",
"     11,12,14,15",
"    </a>",
"    ]. The lightCycler-Parvovirus B19 quantitative assay (Roche Diagnostics, Indianapolis, IN) is highly sensitive for genotype 1 but is not suitable for detecting genotypes 2 or 3. RealArt Parvo B19 LC PCR (Qiagen , Hamburg, GmbH) has been reported to detect all three genotypes by some investigators, but not by others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Appropriate clinical specimens for NAAT analysis include serum, plasma, bone marrow, amniotic fluid, placental and fetal tissues. To ensure diagnostic testing accuracy, it is critical that the laboratory has adequately assessed the analytical performance characteristics (eg, analytical sensitivity, analytical specificity, reproducibility, and limit of detection) of the B19 NAAT prior to its clinical implementation on each sample type that will be analyzed. As with any diagnostic test, NAAT can produce false positive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    false negative results.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A false negative NAAT result can occur if the individual's infection is due to the less common genotypes 2 or 3 if the primer and probe sequences used are located in a non-homologous gene set being used targets a divergent region [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/12,14,15\">",
"       12,14,15",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A false negative NAAT result can also occur when specimens contain inhibitor(s). This is especially true when using a crude cell lysate rather than purified nucleic acid in the NAAT assay. An internal control should be included in each run when analyzing samples so that significant levels of inhibitors can be detected. This approach allows one to be more confident that the negative result is due to lack of detectable target and not to inhibitors in the specimen.",
"     </li>",
"     <li>",
"      A false positive NAAT result can occur because of contamination of either carry-over of genomic DNA during processing of a specimen containing a high viral load, or from high levels of the amplified target generated from a previous run. This is especially true in laboratories using a nested PCR assay for B19 DNA amplification and those do not incorporate pre-amplification contamination control steps. Risk of contamination can be reduced significantly if real-time PCR testing is used. In this approach, amplification and detection are performed in a closed, self-contained vessel that is not opened during the analysis, which eliminates post amplification handling of the amplicons. Another strength of the real-time PCR assay is its ability to be quantitative. However, at this time it does not appear that determining viral load has a prognostic value outside of the blood banking industry [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A false positive result can be seen in immunocompromised patients where B19-specific DNA has been described to be found circulating for months or even years after the infection. This is especially true when testing bone marrow or synovial fluid [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/6,35,56\">",
"       6,35,56",
"      </a>",
"      ]. Thus, detection of B19 DNA, especially at very low levels, does not necessarily indicate an acute or recent infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several real-time PCR assays have been described for detecting B19 DNA, although none have been cleared by the Food and Drug Administration, though some NAAT kits have been CE marked (ie, Roche Molecular Diagnostics, Abbott Molecular, Altona Diagnostics) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/57-61\">",
"     57-61",
"    </a>",
"    ]. Several manufacturers now offer analyte specific reagents for detecting B19 DNA; some have been designed to detect and differentiate between all three genotypes while others do not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, B19 transmission can occur via the administration of blood products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/26-30\">",
"     26-30",
"    </a>",
"    ]; the risk is greatest in those products prepared from large sized plasma pools [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. As a result, there is heightened interest both in Europe and North America for establishing a maximum cutoff for an acceptable viral load in certain blood products. Observations in healthy volunteers suggest that acute B19 infection can be acquired from administration of blood components that contain greater than 10 (log 7) genome",
"    <span class=\"nowrap\">",
"     equivalents/mL",
"    </span>",
"    of B19 DNA. In contrast, patients receiving greater than 10 (log 4) genome",
"    <span class=\"nowrap\">",
"     equivalents/mL",
"    </span>",
"    have not shown evidence of virus transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. The presence of neutralizing activity in all these pools may help to explain the lack of infectivity with exposure to lower viral loads [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/26,62\">",
"     26,62",
"    </a>",
"    ]. With the introduction of a World Health Organization International Standard for B19 DNA (NIBSC",
"    <span class=\"nowrap\">",
"     99/800),",
"    </span>",
"    quantitative PCR assay standardization is possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the fact that contaminated blood products can transmit B19 infection, there are at present no regulations in the United States governing B19 contamination of pooled plasma or blood products. However, many manufacturers voluntarily test plasma minipools for B19 DNA viral load and eliminate those with high levels of B19 virus. Because NAAT can detect not only intact B19 genomes, but also fragments of degraded B19 DNA, it is important to be cautious in interpreting NAAT data from filtered blood products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/66\">",
"     66",
"    </a>",
"    ]. The issue of providing blood products, which have been screened for B19 DNA, to special high-risk populations such as pregnant women, immunocompromised patients, and individuals with chronic anemia may also be addressed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Antigen detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunohistochemical (IHC) techniques can be used to detect B19 antigens in a variety of tissues, especially fetal and placental tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. There are commercially available sources of monoclonal or polyclonal B19 specific antibodies that recognize B19 capsid proteins VP1 and VP2. Antibodies recognizing NS1 protein have been reported, but are not yet commercially available. Although IHC techniques allow for direct visualization of virus within a tissue, it suffers from suboptimal sensitivity compared with NAAT and if used alone for diagnosing B19 infections will miss B19-positive cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Virus isolation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Freshly harvested bone marrow or fetal cord blood, or several continuous cell lines can support low level B19 replication in vitro. However, these in vitro systems have not been used for clinical applications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32312/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13908416\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parvovirus B19 infection occurs worldwide as sporadic cases or within clustered outbreaks. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Parvovirus B19 infection is highly prevalent. More than 70 percent of adults have evidence of B19-specific IgG antibodies. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infected patients are most contagious during the phase of active viral replication and viral shedding, which occurs approximately 5 to 10 days after exposure. During this initial phase, patients may present with a non-specific flu-like illness or may be asymptomatic. During the second phase of illness, more specific symptoms of parvovirus infection include arthralgia, arthritis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      rash. Patients are no longer infectious when exhibiting these clinical characteristics. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Incubation period and infectivity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The three documented modes of transmitting parvovirus B19 include respiratory spread, vertical transmission during pregnancy and hematogenous transmission through blood products. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of diagnostic testing for acute parvovirus B19 infection will depend on the patient's immune status. In immunocompetent individuals, the preferred method is serologic testing to detect circulating B19-specific IgM and IgG antibodies. Among immunocompromised patients or infants, nucleic acid amplification testing (NAAT) is preferred. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Acute infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Previous infection is best confirmed through serologic testing for B19-specific IgG antibodies, which infer immunity. Such testing is helpful in determining susceptibility in a pregnant woman with a history of parvovirus exposure. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Previous infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reactivation of infection occurs in immunocompetent and, more often, among immunocompromised individuals with serologic evidence of past infection. &nbsp;Reactivation is confirmed by demonstrating the continued presence of parvovirus B19 DNA over time through nucleic acid amplification testing. IgM-specific parvovirus antibodies are often detectable during reactivation among those patients with sufficient humoral immunity. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Reactivation of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute infection is demonstrated through serologic detection of B19-specific IgM antibodies to viral capsid antigen. Commercial assays vary both in sensitivity (70 to 100 percent) and specificity (76 to 100 percent). The presence of rheumatoid factor, anti-nuclear antibodies, and Epstein-Barr virus IgM in a specimen can lead to false positive IgM results. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'IgM antibody assays'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serologic testing for past infection using parvovirus B19-specific IgG antibodies has excellent sensitivity and specificity. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'IgG antibody assays'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Detecting B19 DNA using nucleic acid amplification testing (NAAT) is more sensitive than antigen-based detection systems. Appropriate clinical specimens for NAAT analysis include serum, plasma, bone marrow, amniotic fluid, placental and fetal tissues. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Nucleic acid detection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Viral isolation is usually only performed in research laboratories and is not generally available for patient management. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Virus isolation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/1\">",
"      Brown KE. Variants of B19. Dev Biol (Basel) 2004; 118:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/2\">",
"      Chorba T, Coccia P, Holman RC, et al. The role of parvovirus B19 in aplastic crisis and erythema infectiosum (fifth disease). J Infect Dis 1986; 154:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/3\">",
"      Woolf AD, Campion GV, Chishick A, et al. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med 1989; 149:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/4\">",
"      Moffatt S, Yaegashi N, Tada K, et al. Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. J Virol 1998; 72:3018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/5\">",
"      Jordan JA, Butchko AR. Apoptotic activity in villous trophoblast cells during B19 infection correlates with clinical outcome: assessment by the caspase-related M30 Cytodeath antibody. Placenta 2002; 23:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/6\">",
"      Musiani M, Zerbini M, Gentilomi G, et al. Parvovirus B19 clearance from peripheral blood after acute infection. J Infect Dis 1995; 172:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/7\">",
"      Prowse C, Ludlam CA, Yap PL. Human parvovirus B19 and blood products. Vox Sang 1997; 72:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/8\">",
"      Naides SJ. Erythema infectiosum (fifth disease) occurrence in Iowa. Am J Public Health 1988; 78:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/9\">",
"      Serjeant GR, Serjeant BE, Thomas PW, et al. Human parvovirus infection in homozygous sickle cell disease. Lancet 1993; 341:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/10\">",
"      Yamashita K, Matsunaga Y, Taylor-Wiedeman J, Yamazaki S. A significant age shift of the human parvovirus B19 antibody prevalence among young adults in Japan observed in a decade. Jpn J Med Sci Biol 1992; 45:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/11\">",
"      Heegaard ED, Panum Jensen I, Christensen J. Novel PCR assay for differential detection and screening of erythrovirus B19 and erythrovirus V9. J Med Virol 2001; 65:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/12\">",
"      Hokynar K, S&ouml;derlund-Venermo M, Pesonen M, et al. A new parvovirus genotype persistent in human skin. Virology 2002; 302:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/13\">",
"      Nguyen QT, Sifer C, Schneider V, et al. Novel human erythrovirus associated with transient aplastic anemia. J Clin Microbiol 1999; 37:2483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/14\">",
"      Nguyen QT, Wong S, Heegaard ED, Brown KE. Identification and characterization of a second novel human erythrovirus variant, A6. Virology 2002; 301:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/15\">",
"      Servant A, Laperche S, Lallemand F, et al. Genetic diversity within human erythroviruses: identification of three genotypes. J Virol 2002; 76:9124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/16\">",
"      Cohen BJ, Buckley MM. The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol 1988; 25:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/17\">",
"      Kerr S, O'Keeffe G, Kilty C, Doyle S. Undenatured parvovirus B19 antigens are essential for the accurate detection of parvovirus B19 IgG. J Med Virol 1999; 57:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/18\">",
"      Anderson MJ, Higgins PG, Davis LR, et al. Experimental parvoviral infection in humans. J Infect Dis 1985; 152:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/19\">",
"      Gillespie SM, Cartter ML, Asch S, et al. Occupational risk of human parvovirus B19 infection for school and day-care personnel during an outbreak of erythema infectiosum. JAMA 1990; 263:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/20\">",
"      Koch WC, Adler SP. Human parvovirus B19 infections in women of childbearing age and within families. Pediatr Infect Dis J 1989; 8:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/21\">",
"      Cartter ML, Farley TA, Rosengren S, et al. Occupational risk factors for infection with parvovirus B19 among pregnant women. J Infect Dis 1991; 163:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/22\">",
"      Ray SM, Erdman DD, Berschling JD, et al. Nosocomial exposure to parvovirus B19: low risk of transmission to healthcare workers. Infect Control Hosp Epidemiol 1997; 18:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/23\">",
"      Bell LM, Naides SJ, Stoffman P, et al. Human parvovirus B19 infection among hospital staff members after contact with infected patients. N Engl J Med 1989; 321:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/24\">",
"      Dowell SF, T&ouml;r&ouml;k TJ, Thorp JA, et al. Parvovirus B19 infection in hospital workers: community or hospital acquisition? J Infect Dis 1995; 172:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/25\">",
"      Jordan JA. Identification of human parvovirus B19 infection in idiopathic nonimmune hydrops fetalis. Am J Obstet Gynecol 1996; 174:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/26\">",
"      Jordan J, Tiangco B, Kiss J, Koch W. Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients. Vox Sang 1998; 75:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/27\">",
"      McOmish F, Yap PL, Jordan A, et al. Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reaction. J Clin Microbiol 1993; 31:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/28\">",
"      Mortimer PP, Luban NL, Kelleher JF, Cohen BJ. Transmission of serum parvovirus-like virus by clotting-factor concentrates. Lancet 1983; 2:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/29\">",
"      Saldanha J, Minor P. Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufacture. Br J Haematol 1996; 93:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/30\">",
"      Yoto Y, Kudoh T, Haseyama K, et al. Incidence of human parvovirus B19 DNA detection in blood donors. Br J Haematol 1995; 91:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/31\">",
"      Kleinman SH, Glynn SA, Lee TH, et al. Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay. Transfusion 2007; 47:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/32\">",
"      Sharp CP, Lail A, Donfield S, et al. High frequencies of exposure to the novel human parvovirus PARV4 in hemophiliacs and injection drug users, as detected by a serological assay for PARV4 antibodies. J Infect Dis 2009; 200:1119.",
"     </a>",
"    </li>",
"    <li>",
"     Erdman DD. Human parvovirus B19: Laboratory diagnosis. In: Monographs in Virology: Human Parvovirus B19, Anderson LJ, Young NS (Eds), Karger, New York 1997. p.93.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/34\">",
"      Erdman DD, Usher MJ, Tsou C, et al. Human parvovirus B19 specific IgG, IgA, and IgM antibodies and DNA in serum specimens from persons with erythema infectiosum. J Med Virol 1991; 35:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/35\">",
"      Cassinotti P, Burtonboy G, Fopp M, Siegl G. Evidence for persistence of human parvovirus B19 DNA in bone marrow. J Med Virol 1997; 53:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/36\">",
"      Jordan JA. Comparison of a baculovirus-based VP2 enzyme immunoassay (EIA) to an Escherichia coli-based VP1 EIA for detection of human parvovirus B19 immunoglobulin M and immunoglobulin G in sera of pregnant women. J Clin Microbiol 2000; 38:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/37\">",
"      Butchko AR, Jordan JA. Comparison of three commercially available serologic assays used to detect human parvovirus B19-specific immunoglobulin M (IgM) and IgG antibodies in sera of pregnant women. J Clin Microbiol 2004; 42:3191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/38\">",
"      Schwarz TF, J&auml;ger G, Gilch S. Comparison of seven commercial tests for the detection of parvovirus B19-specific IgM. Zentralbl Bakteriol 1997; 285:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/39\">",
"      Beersma MF, Claas EC, Sopaheluakan T, Kroes AC. Parvovirus B19 viral loads in relation to VP1 and VP2 antibody responses in diagnostic blood samples. J Clin Virol 2005; 34:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/40\">",
"      Gallinella G, Zuffi E, Gentilomi G, et al. Relevance of B19 markers in serum samples for a diagnosis of parvovirus B19-correlated diseases. J Med Virol 2003; 71:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/41\">",
"      Manaresi E, Zuffi E, Gallinella G, et al. Differential IgM response to conformational and linear epitopes of parvovirus B19 VP1 and VP2 structural proteins. J Med Virol 2001; 64:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/42\">",
"      Jordan JA. Appreciating differences between immunoassays used to diagnose maternal parvovirus B19 infection: understanding the antigen before interpreting the results. Prim Care Update Ob Gyns 2002; 9:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/43\">",
"      Manaresi E, Gallinella G, Venturoli S, et al. Detection of parvovirus B19 IgG: choice of antigens and serological tests. J Clin Virol 2004; 29:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/44\">",
"      Kajigaya S, Fujii H, Field A, et al. Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions. Proc Natl Acad Sci U S A 1991; 88:4646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/45\">",
"      S&ouml;derlund M, Brown KE, Meurman O, Hedman K. Prokaryotic expression of a VP1 polypeptide antigen for diagnosis by a human parvovirus B19 antibody enzyme immunoassay. J Clin Microbiol 1992; 30:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/46\">",
"      Heegaard ED, Rasksen CJ, Christensen J. Detection of parvovirus B19 NS1-specific antibodies by ELISA and western blotting employing recombinant NS1 protein as antigen. J Med Virol 2002; 67:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/47\">",
"      Ennis O, Corcoran A, Kavanagh K, et al. Baculovirus expression of parvovirus B19 (B19V) NS1: utility in confirming recent infection. J Clin Virol 2001; 22:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/48\">",
"      Searle K, Schalasta G, Enders G. Development of antibodies to the nonstructural protein NS1 of parvovirus B19 during acute symptomatic and subclinical infection in pregnancy: implications for pathogenesis doubtful. J Med Virol 1998; 56:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/49\">",
"      von Poblotzki A, Hemauer A, Gigler A, et al. Antibodies to the nonstructural protein of parvovirus B19 in persistently infected patients: implications for pathogenesis. J Infect Dis 1995; 172:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/50\">",
"      Durigon EL, Erdman DD, Gary GW, et al. Multiple primer pairs for polymerase chain reaction (PCR) amplification of human parvovirus B19 DNA. J Virol Methods 1993; 44:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/51\">",
"      Jordan JA, Faas SJ, Braun ER, Trucco M. Exonuclease-released Fluorescence Detection of Human Parvovirus B19 DNA. Mol Diagn 1996; 1:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/52\">",
"      Skj&ouml;ldebrand-Sparre L, Tolfvenstam T, Papadogiannakis N, et al. Parvovirus B19 infection: association with third-trimester intrauterine fetal death. BJOG 2000; 107:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/53\">",
"      Braham S, Gandhi J, Beard S, Cohen B. Evaluation of the Roche LightCycler parvovirus B19 quantification kit for the diagnosis of parvovirus B19 infections. J Clin Virol 2004; 31:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/54\">",
"      Hokynar K, Norja P, Laitinen H, et al. Detection and differentiation of human parvovirus variants by commercial quantitative real-time PCR tests. J Clin Microbiol 2004; 42:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/55\">",
"      de Haan TR, Beersma MF, Oepkes D, et al. Parvovirus B19 infection in pregnancy: maternal and fetal viral load measurements related to clinical parameters. Prenat Diagn 2007; 27:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/56\">",
"      S&ouml;derlund M, von Essen R, Haapasaari J, et al. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet 1997; 349:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/57\">",
"      Manaresi E, Gallinella G, Zuffi E, et al. Diagnosis and quantitative evaluation of parvovirus B19 infections by real-time PCR in the clinical laboratory. J Med Virol 2002; 67:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/58\">",
"      Aberham C, Pendl C, Gross P, et al. A quantitative, internally controlled real-time PCR Assay for the detection of parvovirus B19 DNA. J Virol Methods 2001; 92:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/59\">",
"      Koppelman MH, Cuypers HT, Emrich T, Zaaijer HL. Quantitative real-time detection of parvovirus B19 DNA in plasma. Transfusion 2004; 44:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/60\">",
"      Saito T, Munakata Y, Fu Y, et al. Evaluation of anti-parvovirus B19 activity in sera by assay using quantitative polymerase chain reaction. J Virol Methods 2003; 107:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/61\">",
"      Schalasta G, Schmid M, Lachmund T, Enders G. LightCycler consensus PCR for rapid and differential detection of human erythrovirus B19 and V9 isolates. J Med Virol 2004; 73:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/62\">",
"      Brown KE, Young NS, Alving BM, Barbosa LH. Parvovirus B19: implications for transfusion medicine. Summary of a workshop. Transfusion 2001; 41:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/63\">",
"      Weimer T, Streichert S, Watson C, Gr&ouml;ner A. High-titer screening PCR: a successful strategy for reducing the parvovirus B19 load in plasma pools for fractionation. Transfusion 2001; 41:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/64\">",
"      Kleinman SH, Glynn SA, Lee TH, et al. A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion. Blood 2009; 114:3677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/65\">",
"      Saldanha J, Lelie N, Yu MW, et al. Establishment of the first World Health Organization International Standard for human parvovirus B19 DNA nucleic acid amplification techniques. Vox Sang 2002; 82:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/66\">",
"      Tsujikawa M, Ohkubo Y, Masuda M, et al. Caution in evaluation of removal of virus by filtration: Misinterpretation due to detection of viral genome fragments by PCR. J Virol Methods 2011; 178:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/67\">",
"      Anderson LJ, Tsou C, Parker RA, et al. Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay. J Clin Microbiol 1986; 24:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/68\">",
"      Kurtzman GJ, Ozawa K, Cohen B, et al. Chronic bone marrow failure due to persistent B19 parvovirus infection. N Engl J Med 1987; 317:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/69\">",
"      Salimans MM, van de Rijke FM, Raap AK, van Elsacker-Niele AM. Detection of parvovirus B19 DNA in fetal tissues by in situ hybridisation and polymerase chain reaction. J Clin Pathol 1989; 42:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/70\">",
"      Munshi NC, Zhou S, Woody MJ, et al. Successful replication of parvovirus B19 in the human megakaryocytic leukemia cell line MB-02. J Virol 1993; 67:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32312/abstract/71\">",
"      Ozawa K, Kurtzman G, Young N. Replication of the B19 parvovirus in human bone marrow cell cultures. Science 1986; 233:883.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8274 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-50DD9E1A11-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_35_32312=[""].join("\n");
var outline_f31_35_32312=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13908416\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Incubation period and infectivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LABORATORY DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      B19 immune status",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Acute infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Previous infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Reactivation of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      B19-specific assays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - IgM antibody assays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - IgG antibody assays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Nucleic acid detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Antigen detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Virus isolation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13908416\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22377?source=related_link\">",
"      Clinical manifestations and pathogenesis of human parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/1/31767?source=related_link\">",
"      Treatment and prevention of parvovirus B19 infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_35_32313="Bone and calcium disorders in HIV-infected patients";
var content_f31_35_32313=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bone and calcium disorders in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/35/32313/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/35/32313/contributors\">",
"     Melissa Weinberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/35/32313/contributors\">",
"     Morris Schambelan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/35/32313/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/35/32313/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/35/32313/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/35/32313/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/35/32313/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the HIV-infected population continues to live longer due to effective antiretroviral therapy (ART), osteopenia and osteoporosis are becoming more common metabolic complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/1\">",
"     1",
"    </a>",
"    ]. Certain lifestyle and hormonal factors, which increase the risk of disordered bone metabolism, are prevalent in HIV-infected patients. These include physical inactivity, suboptimal intake of calcium and vitamin D, cigarette smoking, alcohol and opiate use, depression, and low testosterone levels. Antiretroviral therapy itself may be associated with decreased bone mineral density.",
"   </p>",
"   <p>",
"    This topic will discuss pathogenesis, prevalence, risk factors, screening, and interventions for patients with bone loss. Topics of HIV and aging are discussed elsewhere. Issues of screening and management of osteoporosis in the general population are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/44/26313?source=see_link\">",
"     \"HIV and the older patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3105428\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoporosis is a skeletal disorder characterized by compromised bone strength, which predisposes to an increased risk of fracture. Osteopenia is characterized by low bone mineral density (BMD) and is a precursor to osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=see_link\">",
"     \"Screening for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE OF OSTEOPENIA AND OSTEOPOROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low BMD is one of the factors that predict fracture risk. Although prevalence estimates of low BMD vary considerably, most studies indicate a high prevalence of osteopenia and osteoporosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis, which included 20 cross-sectional studies reporting BMD measurements among 884 HIV-infected patients, demonstrated that 67 percent had reduced BMD with 15 percent meeting criteria for osteoporosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/2\">",
"       2",
"      </a>",
"      ]. Studies performed in ART-na&iuml;ve patients also indicate a higher prevalence of osteopenia than would be expected in age- and sex-matched seronegative adults.",
"     </li>",
"     <li>",
"      In a study of 671 patients in Spain who were followed for a median of 2.5 years, osteopenia and osteoporosis were diagnosed in 48 and 23 percent of patients, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a cross-sectional survey of 492 HIV-infected patients within the Aquitaine cohort, dual-energy X-ray absorptiometry (DXA) was utilized to determine BMD of the total body, lumbar spine, and femoral neck regions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/4\">",
"       4",
"      </a>",
"      ]. Osteopenia was diagnosed in 55 percent of men and 51 percent of women; osteoporosis was diagnosed in 34 percent of men and 8 percent of women. In this cohort, the higher prevalence of low BMD in men than in women may be explained by their slightly older age (median age 43 versus 41 years) and more frequent tobacco use (74 versus 59 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prevalence of osteopenia and osteoporosis may be affected by antiretroviral medications, associated body composition changes, duration of HIV infection, chronic illness, and other concomitant risk factors for bone loss.",
"   </p>",
"   <p>",
"    Emerging data suggest that fracture rates are higher in HIV-infected patient populations than among matched uninfected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/5-10\">",
"     5-10",
"    </a>",
"    ]. A retrospective analysis comparing 8525 patients with HIV and 2,208,792 patients without HIV found an increased fracture prevalence based on ICD-9 coding (2.9 versus 1.9 per 100 persons, p&lt;0.0001) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/5\">",
"     5",
"    </a>",
"    ]. There have also been a few reports of fragility fractures in AIDS patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. As the HIV-infected population ages, prevention of osteoporotic fractures is likely to become a significant therapeutic goal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/44/26313?source=see_link\">",
"     \"HIV and the older patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR BONE LOSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low bone mineral density (BMD) among patients with HIV infection is usually multifactorial, since weight loss, malnutrition, hypogonadism, and malabsorption (leading to vitamin D deficiency) may be present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3105688\">",
"    <span class=\"h2\">",
"     Traditional risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditional risk factors for bone loss such as female gender, low body mass index (BMI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/11\">",
"     11",
"    </a>",
"    ], physical inactivity, steroid use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/12\">",
"     12",
"    </a>",
"    ], advanced age, duration of menopause, smoking, and injection drug use, may act in concert with HIV-associated risk factors. Also, the importance of the status of reproductive function was highlighted by a study of 84 normal-weight, HIV-infected women, that reported reduced bone density among women with oligomenorrhea or elevated follicle-stimulating hormone (FSH) levels compared with women with normal menses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/25/6553?source=see_link&amp;anchor=H13#H13\">",
"     \"Epidemiology and etiology of premenopausal osteoporosis\", section on 'Secondary causes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32473?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology and etiology of osteoporosis in men\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies have demonstrated high rates of vitamin D deficiency among HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], suggesting that other factors, besides malabsorption, may contribute to abnormal levels of this micronutrient. However, it is unclear if these rates of vitamin D deficiency are truly higher than in the general population. In a study of 270 HIV-infected patients on antiretroviral therapy in the United States (85 percent men and 61 percent black race), the prevalence of vitamin D insufficiency (defined as a 25-hydroxy-vitamin D level &lt;20",
"    <span class=\"nowrap\">",
"     ng/L)",
"    </span>",
"    was high, but not statistically different from that among a matched HIV-uninfected control group (69 versus 59 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/15\">",
"     15",
"    </a>",
"    ]. Furthermore, vitamin D deficiency was not associated with low BMD in this cohort. It should be noted, however, that this study reported on a predominantly black population, which may over-represent vitamin D deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3105695\">",
"    <span class=\"h2\">",
"     HIV infection as a risk factor for bone loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV infection itself may be a risk factor for bone loss, as supported by epidemiologic data and studies of pathogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HIV infection leads to chronic T cell activation and increased production of proinflammatory cytokines that enhance osteoclast activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/16\">",
"       16",
"      </a>",
"      ]. Furthermore, HIV proteins decrease bone formation by promoting osteoblast apoptosis (programmed cell death) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an ongoing longitudinal cohort of HIV-seronegative and seropositive men &gt;49 years of age (Cohort of HIV at-risk Aging Men's Prospective Study; CHAMPS), HIV infection was demonstrated to be independently associated with modestly reduced BMD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Observational studies report increased rates of fragility fractures among HIV-infected patients compared with uninfected patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/5,19\">",
"       5,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Treatment-naive patients have a high prevalence of osteopenia, which suggests that uncontrolled viremia can impact BMD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36156172\">",
"    <span class=\"h2\">",
"     Hepatitis C infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with hepatitis C (HCV), regardless of the presence of HIV infection, has been associated with reduced BMD as well as increased fracture risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/10,20,21\">",
"     10,20,21",
"    </a>",
"    ]. In a large cross-sectional study of patients on public health insurance in several of the United States, the incidence of hip fracture, as assessed by diagnostic coding, was higher among those infected with HCV compared with either uninfected or HIV-monoinfected patients (2.7 versus 1.3 and 2 events per 1000 person years, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/10\">",
"     10",
"    </a>",
"    ]. The highest rate of hip fracture was observed among patients coinfected with both HIV and HCV (3.1 events per 1000 person years). Proposed mechanisms have included alterations in calciotropic and gonadotropic hormone levels and weight loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EFFECTS OF MEDICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3596305\">",
"    <span class=\"h2\">",
"     Antiretroviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have noted a decrease in bone mineral density in HIV-infected patients with exposure to antiretroviral therapy (ART), particularly with certain agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    ), but the actual effect on fracture rate is less clear. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7223987\">",
"    <span class=\"h3\">",
"     Osteoporotic fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of ART on the rate of osteoporotic fractures in HIV-infected patients has not been prospectively evaluated. The available data are from retrospective studies of large datasets that employ diagnostic coding to identify and characterize patients. Despite their limitations, these studies suggest that there is not a substantial association between ART and fracture.",
"   </p>",
"   <p>",
"    In a retrospective analysis of about 56,000 HIV-positive men in the United States Veterans Health Administration&rsquo;s registry, 941 patients with probable osteoporotic fractures (wrist, hip, and vertebral fractures) were identified after a mean of 5.4 years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/22\">",
"     22",
"    </a>",
"    ]. After controlling for other osteoporotic risk factors, cumulative ART use was not associated with an increased rate of fracture.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    use specifically was associated with a small but significant increase in the fracture rate (hazard ratios 1.12, 95% CI 1.03-1.21 for every year of tenofovir use), but this was only seen in the subset of patients who entered the cohort in the era of combination ART. Furthermore, the traditional risk factors of age, race, low body mass index, and smoking were substantially more strongly associated with fracture incidence.",
"   </p>",
"   <p>",
"    In an industry-sponsored case-control study, the 2477 HIV-infected patients with a history of nontraumatic fracture were more likely to have advanced HIV disease (41 versus 37 percent) and less likely to have taken ART (51 versus 60 percent) than the 9144 age and gender-matched controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/23\">",
"     23",
"    </a>",
"    ]. This study did not identify an increased risk of fracture with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    . There was an association between fracture and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    exposure, but the small number of events in the subset limits the interpretation of this finding.",
"   </p>",
"   <p>",
"    Further evaluation with prospective studies and longer follow-up are needed to assess more accurately the fracture risk with specific antiretroviral agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7224217\">",
"    <span class=\"h3\">",
"     Bone mineral density",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h4\">",
"     Treatment-naive versus treatment-experienced patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a meta-analysis of ten studies comparing ART-na&iuml;ve (n = 202) with ART-treated (n = 824) patients, there was a 2.5-fold increase in the odds of low bone mineral density (BMD) in ART-exposed patients; however, most of these studies did not adjust for HIV disease severity or duration of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies published since the report of this meta-analysis further suggest that initiation of ART induces a marked loss of BMD ranging from 2 to 6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. Further studies are needed to clarify the clinical significance of these BMD declines and the contribution of ART-associated body composition changes to the development of osteopenia and osteoporosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h4\">",
"     Continuous versus discontinuous ART",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SMART trial (Strategies for Management of Anti-HIV Therapy) was designed to identify whether continuous versus intermittent ART would maximize benefit while minimizing risk of drug toxicity. The data safety monitoring board stopped the study early due to increased clinical progression in the drug conservation arm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/51/10039?source=see_link\">",
"     \"Structured treatment interruptions in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A subgroup in this trial (n = 116 intermittent therapy arm; n = 98 continuous therapy arm) underwent hip and spine BMD evaluations through DXA and spine BMD by quantitative computed tomography (qCT) over a mean follow-up of 2.4 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/28\">",
"     28",
"    </a>",
"    ]. BMD declines were significantly lower in patients randomly assigned to the continuous therapy versus the intermittent therapy group, although no consistent drug-associated effect could be discerned. In the parent trial, 10 of 2753 patients in the continuous therapy arm versus two of the 2720 patients in the intermittent therapy arm reported serious fractures (hazard ratio 4.9; 95% CI 1.1-22.5).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h4\">",
"     Tenofovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initiation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    -containing ART regimens has been shown to lead to initial, modest bone loss that subsequently stabilizes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial of either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      , patients in the tenofovir arm had a significantly greater percent change from baseline in lumbar spine BMD at 48 weeks compared to those in the stavudine arm. No further decrement was seen at 144 weeks of follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the STEAL trial of 357 virologically suppressed patients, there was more bone loss among patients who were switched to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      -containing ART than among those patients who were switched to abacavir-based ART [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two prospective trials involving treatment-naive patients found that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      -containing ART led to significantly greater declines in spine and hip BMD than did abacavir-containing regimens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/26,31\">",
"       26,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 283 men, 76 premenopausal women, and 20 postmenopausal women, greater loss of total BMD was associated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    administration has also been associated with Fanconi's syndrome, which is characterized by renal phosphate wasting, hypophosphatemia, metabolic acidosis, glycosuria, and aminoaciduria; skeletal complications of this syndrome include osteomalacia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h4\">",
"     Protease inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some data point to a negative effect of PIs on BMD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/24,31,34\">",
"     24,31,34",
"    </a>",
"    ]. As an example, a substudy of the AIDS Clinical Trial Group trial (A5202) found that patients randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    had greater losses of BMD in the spine, but not the hip, than patients assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/31\">",
"     31",
"    </a>",
"    ]. However, other cross-sectional and longitudinal studies have not supported this finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/4,13,18,35-39\">",
"     4,13,18,35-39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A longitudinal study of 128 HIV-infected patients, 93 of whom were followed for 72 weeks, found a weak association with protease inhibitor use that was abrogated after controlling for traditional risk factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/36\">",
"       36",
"      </a>",
"      ]. Another longitudinal study also noted similar observations and demonstrated that low body mass index was a significant predictor of low BMD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a cross-sectional study of 142 study participants, osteopenia and osteoporosis were demonstrated more frequently in HIV-seropositive patients compared with HIV-seronegative controls. However, there were no differences in bone density among HIV-seropositive patients who were treatment-na&iuml;ve or treatment-experienced, regardless of regimen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a cohort of women greater than 40 years of age, the majority of whom had used illicit drugs, those with HIV infection had reduced BMD in the femoral neck and spine, independent of antiretroviral exposure, when compared with controls. Significant risk factors included non-black race, low weight, and use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      maintenance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    From these studies, it appears that traditional risk factors or HIV itself may contribute to decreased bone density in HIV-infected individuals, rather than protease inhibitor exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities in calcium concentration may also be an adverse effect of several medications used in the treatment of the complications of HIV such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/54/12137?source=see_link\">",
"     recombinant human growth hormone",
"    </a>",
"    . Other medications used in patients with HIV that may accelerate bone loss include corticosteroids and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Opiates have also been associated with low BMD in a study of 14 male heroin addicts who showed an 11 percent reduction in lumbar BMD compared with previous users and healthy age- and sex-matched controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/40\">",
"     40",
"    </a>",
"    ]. Associated hypogonadism in chronic opiate users may, at least partially, explain their reduced BMD. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Risk factors for bone loss'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ALTERATIONS IN BONE AND CALCIUM METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in bone metabolism rarely result from direct viral infection of bone or parathyroid glands. More commonly, systemic inflammation and circulating cytokines, as well as HIV-associated opportunistic infections (OIs), neoplasms,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medications affect bone through indirect mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95085076\">",
"    <span class=\"h2\">",
"     Markers of bone metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biochemical markers of bone metabolism were measured in a cross-sectional analysis of 73 patients; those with advanced HIV disease demonstrated low levels of osteocalcin (a marker of bone formation) and high levels of C-telopeptide (a marker of bone resorption). In 16 of these patients who were followed after the initiation of antiretroviral therapy (ART), osteocalcin levels rose and were correlated with C-telopeptide, suggesting a beneficial effect of ART on bone remodeling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95085090\">",
"    <span class=\"h2\">",
"     Parathyroid hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired parathyroid (PTH) secretion and action have been reported in patients with HIV infection, even in the absence of parathyroid infiltrative disease. Not only are baseline PTH levels lower in HIV-infected individuals than controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/43\">",
"     43",
"    </a>",
"    ], but a study of six AIDS patients who underwent EDTA-induced hypocalcemia showed diminished PTH response at all calcium concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    has been associated with higher PTH levels than otherwise seen in those with HIV infection. In a trial of young adults infected with HIV on ART, PTH levels were higher in the 120 patients on regimens containing tenofovir than in the 87 on regimens without tenofovir (mean 48 versus 31",
"    <span class=\"nowrap\">",
"     pg/mL),",
"    </span>",
"    independent of baseline serum 25-OH vitamin D levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/45\">",
"     45",
"    </a>",
"    ]. Although statistically significant, this difference is of uncertain clinical significance. Clinically important outcomes (eg, bone density, fracture) were not reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95085097\">",
"    <span class=\"h2\">",
"     Calcium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia can result from malignant (eg, lymphoma) or granulomatous processes associated with extrarenal 1-alpha-hydroxylation of 25-hydroxy-vitamin D to the active 1,25-dihydroxy-vitamin D, resulting in enhanced intestinal calcium absorption. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/22/28007?source=see_link\">",
"     \"Etiology of hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several case reports have described hypercalcemia in association with the immune reconstitution inflammatory syndrome that occurs frequently after the initiation of ART. Associated infections and diseases have included tuberculosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/46,47\">",
"     46,47",
"    </a>",
"    ], mycobacterium avium complex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/48\">",
"     48",
"    </a>",
"    ], cryptococcus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/49\">",
"     49",
"    </a>",
"    ], and sarcoidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypocalcemia, after adjusting for serum albumin, was found in 6.5 percent of HIV-seropositive patients compared with 1.1 percent of controls. In 10 of these 21 patients with AIDS, vitamin D deficiency was found to be the etiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Published guidelines for the management of low BMD in the general US population recommend a DXA for persons of any age with a fragility fracture, women &gt;65 years of age, and men &gt;70 years of age. For those with an additional risk factor, the recommendation is to perform a DXA scan in postmenopausal women and men &gt;50 years of age. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=see_link\">",
"     \"Screening for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based on the results of several prospective and retrospective studies, an expert panel suggested that HIV infection itself should be considered a risk factor for osteoporosis. The panel recommended a DXA scan for all HIV-infected postmenopausal women and men &gt;50 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/52\">",
"     52",
"    </a>",
"    ]. These recommendations are somewhat different from those of the HIV primary care guidelines from the Infectious Diseases Society of America, which suggest a DXA scan for HIV-infected subjects &gt;50 years of age with additional risk factors for osteopenia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/53\">",
"     53",
"    </a>",
"    ]. Additional risk factors for bone loss include patients with low BMI, smoking history, hypogonadism, or early menopause (",
"    <a class=\"graphic graphic_algorithm graphicRef66950 \" href=\"mobipreview.htm?43/43/44721\">",
"     algorithm 1",
"    </a>",
"    ). Since these other factors are so prevalent among HIV-infected patients, most would qualify for screening, whether HIV is considered a risk factor or not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11203000\">",
"    <span class=\"h2\">",
"     Secondary causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;If osteoporosis is present (based on T-score &lt;-2.5 or presence of a pathological fracture), screening for secondary causes of osteoporosis should also be sought and treated appropriately, including evaluation for hypogonadism",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    wasting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend checking the following laboratory studies to evaluate secondary causes of bone loss: complete blood count, calcium, albumin, phosphorus, creatinine, ALT, alkaline phosphatase, 25-OH-vitamin D, intact PTH, TSH, morning total, testosterone (in men), and 24-hour urine calcium and creatinine. Measuring 25-hydroxyvitamin D levels, which indicate the body's vitamin D stores, may be especially useful given the high prevalence of vitamin D insufficiency reported in HIV-infected populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Evaluation for other secondary causes may be indicated based on the patient&rsquo;s history",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    physical examination. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=see_link\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11128?source=see_link\">",
"     \"Diagnosis and evaluation of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36213?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of osteoporosis in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6114494\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Making recommendations for the management of low BMD in HIV-infected populations is especially challenging, given that most experience in the treatment of osteopenia and osteoporosis has been in post-menopausal women. Since age has an important effect on fracture risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/57\">",
"     57",
"    </a>",
"    ], and HIV-infected individuals tend to be younger than other patients with osteoporosis, BMD alone may overestimate true fracture risk in these patients.",
"   </p>",
"   <p>",
"    The World Health Organization Fracture Risk Assessment Tool (FRAX&reg;) (",
"    <a class=\"external\" href=\"file://www.shef.ac.uk/FRAX/\">",
"     file://www.shef.ac.uk/FRAX/",
"    </a>",
"    ) was developed to predict 10-year probability of fracture based on clinical risk factors (eg, age, family history, smoking, glucocorticoid use) and BMD at the femoral neck. The FRAX model, however, has not been validated in the HIV-infected population. In a study of 153 adults with HIV infection, of whom 42 percent had low BMD, only 3 (2.2 percent) had a 10-year probability of major osteoporotic fracture &gt;20 percent by the FRAX scoring system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/58\">",
"     58",
"    </a>",
"    ]. Longitudinal studies documenting the relationship between low BMD and fracture risk in the HIV-infected population are clearly needed.",
"   </p>",
"   <p>",
"    Treatment of osteopenia and osteoporosis in older HIV-positive patients does not differ from recommendations in older HIV-negative individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/59\">",
"     59",
"    </a>",
"    ]. Treatment approaches can include both lifestyle changes and pharmacologic therapy. In accordance with the National Osteoporosis Foundation guidelines, pharmacologic treatment of osteoporosis is recommended for:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postmenopausal women and men &gt;50 years with a T-score of the femoral neck or lumbar spine less than or equal to -2.5",
"     </li>",
"     <li>",
"      Patients with a history of fragility fracture of the spine or hip",
"     </li>",
"     <li>",
"      Patients with low bone mass (T-score between -1 and -2.5 at the femoral neck or lumbar spine) and high probability of a major fracture, based on the World Health Organization&rsquo;s (WHO) Fracture Risk Assessment Tool (FRAX). A significant risk includes a 10-year probability of fracture that is &gt;3 percent for the hip or &gt;20 percent for any major osteoporotic fracture.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Lifestyle changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lifestyle changes such as smoking cessation, weight-bearing exercise, and optimization of calcium and vitamin D intake can lead to modest improvements in BMD and should be encouraged. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Nonpharmacologic therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of osteoporosis in men\", section on 'Lifestyle measures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Bisphosphonate therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bisphosphonates are pyrophosphate analogues that inhibit bone resorption by binding to hydroxyapatite crystals. They are generally considered first-line therapy for osteoporosis. However, few studies in HIV-infected patients have been published.",
"   </p>",
"   <p>",
"    Pharmacologic therapy for osteoporosis in HIV-infected patients should be considered carefully before initiation, given the lack of prospective data on fracture in this patient population. Long-term side effects are also not known. This is a very important issue since HIV-infected patients may be initiating therapy at a much younger age than other individuals for whom treatment would be indicated (eg, post-menopausal women). We would, however, recommend therapy for patients who have experienced a nontraumatic fracture, regardless of age. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Pharmacologic therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of osteoporosis in men\", section on 'Pharmacologic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies suggesting benefit of bisphosphonates in HIV-infected patients are highlighted below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Alendronate",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 48-week prospective, randomized, open-label study of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      (70 mg once weekly) administered in combination with calcium and vitamin D in 31 HIV-seropositive subjects, there was a significant increase in lumbar spine BMD compared with subjects taking calcium and vitamin D alone (5.2 versus 1.3 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another small, open-label study of 25 HIV-infected individuals with osteoporosis evaluated the added efficacy of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      plus dietary counseling compared to counseling alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/61\">",
"       61",
"      </a>",
"      ]. Patients randomly assigned to the alendronate arm demonstrated significant improvements in lumbar and hip BMD and reduced rates of osteoporosis (27 versus 96 percent) compared to counseling alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/61\">",
"       61",
"      </a>",
"      ]. Alendronate also reduces bone resorption markers in patients with HIV infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective, randomized, placebo-controlled trial (AIDS Clinical Trial Group Study 5163) evaluated the effectiveness of calcium and vitamin D supplementation compared to",
"      <span class=\"nowrap\">",
"       calcium/vitamin",
"      </span>",
"      D with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      in 58 male and 24 female HIV-infected patients with decreased BMD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/63\">",
"       63",
"      </a>",
"      ]. Patients randomly assigned to the alendronate arm had significant improvements in BMD at the lumbar spine, total hip, and trochanter, compared to those assigned to supplementation alone. Alendronate was also well tolerated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Zoledronic Acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     Zoledronic acid",
"    </a>",
"    is a bisphosphonate that is administered by the intravenous route as an annual infusion; this offers the potential for greater adherence. Two studies have demonstrated increases in BMD in HIV-infected patients with bone loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A two-year randomized, placebo-controlled study of 43 HIV-infected men with mild bone loss (T-score &lt;-0.5) treated with annual infusions of 4 mg",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      showed significant increases in BMD in the lumbar spine (8.9 versus 2.6 percent) and in the total hip (3.8 versus 0.8) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/65\">",
"       65",
"      </a>",
"      ]. These improvements in BMD persisted in the subset of subjects that were followed for an additional 12 months without another dose of zoledronic acid and bone turnover markers remained suppressed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A placebo-controlled trial of 27 HIV-infected men and 3 HIV-infected women assessed the effect of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      on patients with osteopenia and osteoporosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/64\">",
"       64",
"      </a>",
"      ]. BMD increased and bone resorption markers decreased in zoledronic acid recipients compared to patients in the placebo arm at 12 months. No infusion reactions were noted, but one patient developed uveitis, a known complication of zoledronic acid.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Calcium and vitamin D supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In November 2010, the Institute of Medicine released a report establishing reference dietary intakes for calcium and vitamin D, depending on age and gender (",
"    <a class=\"graphic graphic_table graphicRef71669 \" href=\"mobipreview.htm?26/10/26797\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/67\">",
"     67",
"    </a>",
"    ]. The IOM committee concluded that 25-hydroxy-vitamin D levels above 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    are adequate for bone health in most individuals. In our HIV-infected patients with osteoporosis and 25-hydroxy-vitamin D levels below 20",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    we generally recommend at least 800 international units of vitamin D daily, as recommended for older HIV-seronegative adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/67\">",
"     67",
"    </a>",
"    ]. Clinical trial data assessing the optimal dose in HIV-infected patients are not available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other medications used in the treatment of osteoporosis such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/22/6501?source=see_link\">",
"     teriparatide (recombinant human parathyroid hormone (1-34))",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    , calcitonin, hormone replacement therapy with estrogen",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progesterone, and selective estrogen receptor modulators (e.g.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    ) have not been specifically studied in HIV-infected populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Switching ART regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although certain ART regimens may be associated with greater decreases in BMD, there is no evidence to suggest that switching ART will improve BMD and reduce fracture risk in those with established osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/52\">",
"     52",
"    </a>",
"    ]. In one small study that evaluated 18 patients who switched from a protease inhibitor-based regimen to a non-nucleoside reverse transcriptase inhibitor-based regimen, no improvements in BMD were observed on DXA scanning after 48 weeks of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/68\">",
"     68",
"    </a>",
"    ]. Since there is no evidence that changing ART regimens will improve BMD, this approach is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     OSTEONECROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteonecrosis, also called avascular necrosis, occurs when there is insufficient circulation to an area of bone and usually presents as either unilateral or bilateral bone or joint pain.",
"   </p>",
"   <p>",
"    Osteonecrosis has been described in HIV-infected individuals in several case reports and case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/8\">",
"     8",
"    </a>",
"    ]. A remarkably high prevalence of avascular necrosis of the hip (4.4 percent) was detected by MRI in a cross-sectional study in 339 asymptomatic HIV-infected patients as compared with no cases detected among the non-infected controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32313/abstract/69\">",
"     69",
"    </a>",
"    ]. Although this study focused on the hip, avascular necrosis can affect other joints such as the shoulder. Some patients, but not all, have other identifiable risk factors for osteonecrosis, including prior glucocorticoid exposure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/43/28346?source=see_link\">",
"     \"Osteonecrosis (avascular necrosis of bone)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mainstay of therapy remains surgical intervention to alleviate symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Changes in bone metabolism rarely result from direct HIV infection of bone or parathyroid glands. More commonly, systemic inflammation and circulating cytokines, as well as HIV-associated opportunistic infections (OIs), neoplasms,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      medications have indirect effects on bone metabolism. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Alterations in bone and calcium metabolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although prevalence estimates of low bone mineral density (BMD) vary considerably, studies indicate that HIV-infected patients are at increased risk of osteoporosis and fracture compared with HIV-uninfected individuals. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevalence of osteopenia and osteoporosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Low BMD among patients with HIV infection is usually multifactorial, since weight loss, malnutrition, malabsorption (leading to vitamin D deficiency), and hypogonadism may be present in addition to traditional risk factors, such as female gender, low body mass index, smoking, and opiate use. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors for bone loss'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV infection itself may lead to bone loss by promoting osteoclast activity and osteoblast cell death. (See",
"      <a class=\"local\" href=\"#H3105695\">",
"       'HIV infection as a risk factor for bone loss'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antiretroviral therapy, particularly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      , is associated with loss of BMD, although the effect on fracture rate itself is not well defined. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Effects of medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest screening for osteoporosis in HIV-infected men and women starting at 50 years of age (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      When osteoporosis is confirmed, secondary causes of bone loss should be excluded. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Screening'",
"      </a>",
"      above.) The therapy of osteoporosis in HIV-infected patients does not differ from that in the uninfected. For HIV-infected postmenopausal women and men with established osteoporosis (T-score &le;-2.5) or any HIV-infected patient with fragility fracture, we initiate pharmacologic therapy. For pharmacologic therapy in HIV-infected patients, we suggest bisphosphonates as first-line therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Other pharmacologic agents (parathyroid hormone, selective estrogen receptor modulators,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      ) have not been adequately studied in HIV-infected patients. (See",
"      <a class=\"local\" href=\"#H6114494\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H40#H40\">",
"       \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Summary and recommendations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link&amp;anchor=H19#H19\">",
"       \"Treatment of osteoporosis in men\", section on 'Summary and Recommendations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=see_link&amp;anchor=H6#H6\">",
"       \"Evaluation and treatment of premenopausal osteoporosis\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Osteonecrosis has been described in HIV-infected individuals in several case reports and case series. The mainstay of therapy remains surgical intervention to alleviate symptoms. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Osteonecrosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/1\">",
"      Borderi M, Gibellini D, Vescini F, et al. Metabolic bone disease in HIV infection. AIDS 2009; 23:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/2\">",
"      Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/3\">",
"      Bonjoch A, Figueras M, Estany C, et al. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS 2010; 24:2827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/4\">",
"      Cazanave C, Dupon M, Lavignolle-Aurillac V, et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 2008; 22:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/5\">",
"      Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008; 93:3499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/6\">",
"      McComsey GA, Huang JS, Woolley IJ, et al. Fragility fractures in HIV-infected patients: need for better understanding of diagnosis and management. J Int Assoc Physicians AIDS Care (Chic) 2004; 3:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/7\">",
"      Stephens EA, Das R, Madge S, et al. Symptomatic osteoporosis in two young HIV-positive African women. AIDS 1999; 13:2605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/8\">",
"      Martin K, Lawson-Ayayi S, Miremont-Salam&eacute; G, et al. Symptomatic bone disorders in HIV-infected patients: incidence in the Aquitaine cohort (1999-2002). HIV Med 2004; 5:421.",
"     </a>",
"    </li>",
"    <li>",
"     Dao C, et al. Higher and increasing rates of fracture among HIV-infected persons in the HIV Outpatient Study compared to the general US population. In: Program and abstracts of the 17 Conference on Retroviruses and Opportunistic Infections, 18 February 2010, San Francisco, CA (Accessed on January 28, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/10\">",
"      Lo Re V 3rd, Volk J, Newcomb CW, et al. Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection. Hepatology 2012; 56:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/11\">",
"      Bolland MJ, Grey AB, Horne AM, et al. Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy. Clin Endocrinol (Oxf) 2006; 65:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/12\">",
"      Jacobson DL, Spiegelman D, Knox TK, Wilson IB. Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr 2008; 49:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/13\">",
"      Dolan SE, Huang JS, Killilea KM, et al. Reduced bone density in HIV-infected women. AIDS 2004; 18:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/14\">",
"      Mueller NJ, Fux CA, Ledergerber B, et al. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS 2010; 24:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/15\">",
"      Sherwood JE, Mesner OC, Weintrob AC, et al. Vitamin D deficiency and its association with low bone mineral density, HIV-related factors, hospitalization, and death in a predominantly black HIV-infected cohort. Clin Infect Dis 2012; 55:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/16\">",
"      Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/17\">",
"      Gibellini D, De Crignis E, Ponti C, et al. HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation. J Med Virol 2008; 80:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/18\">",
"      Arnsten JH, Freeman R, Howard AA, et al. HIV infection and bone mineral density in middle-aged women. Clin Infect Dis 2006; 42:1014.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.retroconference.org/2010/Abstracts/37582.htm (Accessed on September 21, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/20\">",
"      Yin MT, Shi Q, Hoover DR, et al. Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study. AIDS 2010; 24:2679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/21\">",
"      Collier J. Bone disorders in chronic liver disease. Hepatology 2007; 46:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/22\">",
"      Bedimo R, Maalouf NM, Zhang S, et al. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS 2012; 26:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/23\">",
"      Mundy LM, Youk AO, McComsey GA, Bowlin SJ. Overall benefit of antiretroviral treatment on the risk of fracture in HIV: nested case-control analysis in a health-insured population. AIDS 2012; 26:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/24\">",
"      Duvivier C, Kolta S, Assoumou L, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009; 23:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/25\">",
"      Brown TT, McComsey GA, King MS, et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009; 51:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/26\">",
"      Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010; 51:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/27\">",
"      Mulligan K, Harris DR, Emmanuel P, et al. Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent Trials Network Study 021B. Clin Infect Dis 2012; 55:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/28\">",
"      Grund B, Peng G, Gibert CL, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS 2009; 23:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/29\">",
"      Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.retroconference.org/2009/Abstracts/33890.htm (Accessed on September 21, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/31\">",
"      McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011; 203:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/32\">",
"      Earle KE, Seneviratne T, Shaker J, Shoback D. Fanconi's syndrome in HIV+ adults: report of three cases and literature review. J Bone Miner Res 2004; 19:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/33\">",
"      Perrot S, Aslangul E, Szwebel T, et al. Bone pain due to fractures revealing osteomalacia related to tenofovir-induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient. J Clin Rheumatol 2009; 15:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/34\">",
"      Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000; 14:F63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/35\">",
"      Arnsten JH, Freeman R, Howard AA, et al. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 2007; 21:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/36\">",
"      Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003; 36:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/37\">",
"      Nolan D, Upton R, McKinnon E, et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 2001; 15:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/38\">",
"      Dub&eacute; MP, Qian D, Edmondson-Melan&ccedil;on H, et al. Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis 2002; 35:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/39\">",
"      Bruera D, Luna N, David DO, et al. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 2003; 17:1917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/40\">",
"      Pedrazzoni M, Vescovi PP, Maninetti L, et al. Effects of chronic heroin abuse on bone and mineral metabolism. Acta Endocrinol (Copenh) 1993; 129:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/41\">",
"      K&uuml;hne CA, Heufelder AE, Hofbauer LC. Bone and mineral metabolism in human immunodeficiency virus infection. J Bone Miner Res 2001; 16:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/42\">",
"      Aukrust P, Haug CJ, Ueland T, et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 1999; 84:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/43\">",
"      Hellman P, Albert J, Gidlund M, et al. Impaired parathyroid hormone release in human immunodeficiency virus infection. AIDS Res Hum Retroviruses 1994; 10:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/44\">",
"      Jaeger P, Otto S, Speck RF, et al. Altered parathyroid gland function in severely immunocompromised patients infected with human immunodeficiency virus. J Clin Endocrinol Metab 1994; 79:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/45\">",
"      Havens PL, Stephensen CB, Hazra R, et al. Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial. Clin Infect Dis 2012; 54:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/46\">",
"      Ferrand RA, Elgalib A, Newsholme W, et al. Hypercalcaemia complicating immune reconstitution in an HIV-infected patient with disseminated tuberculosis. Int J STD AIDS 2006; 17:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/47\">",
"      Lawn SD, Macallan DC. Hypercalcemia: a manifestation of immune reconstitution complicating tuberculosis in an HIV-infected person. Clin Infect Dis 2004; 38:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/48\">",
"      Playford EG, Bansal AS, Looke DF, et al. Hypercalcaemia and elevated 1,25(OH)(2)D(3) levels associated with disseminated Mycobacterium avium infection in AIDS. J Infect 2001; 42:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/49\">",
"      Jenny-Avital ER, Abadi M. Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy. Clin Infect Dis 2002; 35:e128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/50\">",
"      Ferrand RA, Cartledge JD, Connolly J, et al. Immune reconstitution sarcoidosis presenting with hypercalcaemia and renal failure in HIV infection. Int J STD AIDS 2007; 18:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/51\">",
"      Kuehn EW, Anders HJ, Bogner JR, et al. Hypocalcaemia in HIV infection and AIDS. J Intern Med 1999; 245:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/52\">",
"      McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis 2010; 51:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/53\">",
"      Aberg JA, Kaplan JE, Libman H, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/54\">",
"      Brown TT, McComsey GA. Osteopenia and osteoporosis in patients with HIV: a review of current concepts. Curr Infect Dis Rep 2006; 8:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/55\">",
"      Garc&iacute;a Aparicio AM, Mu&ntilde;oz Fern&aacute;ndez S, Gonz&aacute;lez J, et al. Abnormalities in the bone mineral metabolism in HIV-infected patients. Clin Rheumatol 2006; 25:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/56\">",
"      Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M, et al. Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses 2008; 24:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/57\">",
"      Riggs BL, Melton LJ 3rd. Involutional osteoporosis. N Engl J Med 1986; 314:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/58\">",
"      Calmy A, Fux CA, Norris R, et al. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis 2009; 200:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/59\">",
"      Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002; 31:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/60\">",
"      Mondy K, Powderly WG, Claxton SA, et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr 2005; 38:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/61\">",
"      Guaraldi G, Orlando G, Madeddu G, et al. Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. HIV Clin Trials 2004; 5:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/62\">",
"      Negredo E, Mart&iacute;nez-L&oacute;pez E, Paredes R, et al. Reversal of HIV-1-associated osteoporosis with once-weekly alendronate. AIDS 2005; 19:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/63\">",
"      McComsey GA, Kendall MA, Tebas P, et al. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS 2007; 21:2473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/64\">",
"      Huang J, Meixner L, Fernandez S, McCutchan JA. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS 2009; 23:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/65\">",
"      Bolland MJ, Grey AB, Horne AM, et al. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab 2007; 92:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/66\">",
"      Bolland MJ, Grey AB, Horne AM, et al. Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months. J Bone Miner Res 2008; 23:1304.",
"     </a>",
"    </li>",
"    <li>",
"     Dietary Reference Intakes for Calcium and Vitamin D. Institute of Medicine Consensus Report. Released November 30, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/68\">",
"      Tebas P, Yarasheski K, Henry K, et al. Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS Res Hum Retroviruses 2004; 20:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32313/abstract/69\">",
"      Miller KD, Masur H, Jones EC, et al. High prevalence of osteonecrosis of the femoral head in HIV-infected adults. Ann Intern Med 2002; 137:17.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3738 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-EBC78AF0D7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_35_32313=[""].join("\n");
var outline_f31_35_32313=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3105428\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE OF OSTEOPENIA AND OSTEOPOROSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS FOR BONE LOSS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3105688\">",
"      Traditional risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3105695\">",
"      HIV infection as a risk factor for bone loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36156172\">",
"      Hepatitis C infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EFFECTS OF MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3596305\">",
"      Antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7223987\">",
"      - Osteoporotic fracture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7224217\">",
"      - Bone mineral density",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Treatment-naive versus treatment-experienced patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Continuous versus discontinuous ART",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Tenofovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ALTERATIONS IN BONE AND CALCIUM METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95085076\">",
"      Markers of bone metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95085090\">",
"      Parathyroid hormone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95085097\">",
"      Calcium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11203000\">",
"      Secondary causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6114494\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Lifestyle changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Bisphosphonate therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Alendronate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Zoledronic Acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Calcium and vitamin D supplementation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other modalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Switching ART regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      OSTEONECROSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3738\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3738|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?43/43/44721\" title=\"algorithm 1\">",
"      Approach to bone disorders in HIV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3738|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/10/26797\" title=\"table 1\">",
"      IOM DRIs for calcium and vitamin D",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36213?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11128?source=related_link\">",
"      Diagnosis and evaluation of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32473?source=related_link\">",
"      Epidemiology and etiology of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/25/6553?source=related_link\">",
"      Epidemiology and etiology of premenopausal osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/22/28007?source=related_link\">",
"      Etiology of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=related_link\">",
"      Evaluation and treatment of premenopausal osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/44/26313?source=related_link\">",
"      HIV and the older patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/43/28346?source=related_link\">",
"      Osteonecrosis (avascular necrosis of bone)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=related_link\">",
"      Screening for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/51/10039?source=related_link\">",
"      Structured treatment interruptions in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=related_link\">",
"      Treatment of osteoporosis in men",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_35_32314="Statins: Actions, side effects, and administration";
var content_f31_35_32314=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Statins: Actions, side effects, and administration",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/35/32314/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/35/32314/contributors\">",
"     Robert S Rosenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/35/32314/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/35/32314/contributors\">",
"     Mason W Freeman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/35/32314/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/35/32314/contributors\">",
"     David M Rind, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/35/32314/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipid altering agents encompass several classes of drugs that include HMG CoA reductase (hydroxymethylglutaryl CoA reductase) inhibitors or statins, fibric acid derivatives, bile acid sequestrants, cholesterol absorption inhibitors, and nicotinic acid. These drugs differ with respect to mechanism of action and to the degree and type of lipid lowering. Thus, the indications for a particular drug are influenced by the underlying lipid abnormality. Conventional dosing regimens and common adverse reactions are described in a table (",
"    <a class=\"graphic graphic_table graphicRef77498 \" href=\"mobipreview.htm?28/1/28701\">",
"     table 1",
"    </a>",
"    ) and the range of expected changes in the lipid profile are listed in a separate table (",
"    <a class=\"graphic graphic_table graphicRef75715 \" href=\"mobipreview.htm?21/47/22268\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Lipid lowering, at least with statins, is beneficial in patients with dyslipidemias for both primary and secondary prevention of coronary heart disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/50/19240?source=see_link\">",
"     \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanisms of benefit seen with lipid lowering are incompletely understood. Regression of atherosclerosis occurs in only a minority of patients; furthermore, clinical benefits of lipid lowering are seen in as little as six months, before significant regression could occur. Thus, other factors must contribute; these include plaque stabilization, reversal of endothelial dysfunction, and decreased thrombogenicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The characteristics and efficacy of the statins will be reviewed here (",
"    <a class=\"graphic graphic_table graphicRef53730 \" href=\"mobipreview.htm?14/30/14829\">",
"     table 3",
"    </a>",
"    ). Possible noncardiovascular benefits of statins are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10230?source=see_link\">",
"     \"Statins: Possible noncardiovascular benefits\"",
"    </a>",
"    .) The efficacy of fibrates, lipid lowering drugs other than statins and fibrates, and diet and dietary supplements are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/39/7800?source=see_link\">",
"     \"Lipid lowering with fibric acid derivatives\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42217?source=see_link\">",
"     \"Lipid lowering with drugs other than statins and fibrates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/51/28474?source=see_link\">",
"     \"Lipid lowering with diet or dietary supplements\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapeutic decision making in patients with elevated lipid levels, including indications for and dosing of statins, is discussed in detail separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=see_link\">",
"       \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link\">",
"       \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=see_link\">",
"       \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Currently available statins include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    , and, in some countries,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/56/9095?source=see_link\">",
"     pitavastatin",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef53730 \" href=\"mobipreview.htm?14/30/14829\">",
"     table 3",
"    </a>",
"    ). These agents are competitive inhibitors of HMG CoA reductase, the rate-limiting step in cholesterol biosynthesis (",
"    <a class=\"graphic graphic_figure graphicRef57263 \" href=\"mobipreview.htm?43/8/44175\">",
"     figure 1",
"    </a>",
"    ). They occupy a portion of the binding site of HMG CoA, blocking access of this substrate to the active site on the enzyme [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A reduction in intrahepatic cholesterol leads to an increase in LDL receptor turnover that results from an enhanced rate of hepatic LDL receptor cycling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/2\">",
"     2",
"    </a>",
"    ]. Statins also reduce VLDL production, via an effect mediated by hepatic apo B secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], and it is associated with a diminished rate of recovery of HMG CoA reductase activity after drug treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of the statins have modest HDL-cholesterol (HDL-C) raising properties (about 5 percent), although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    has a larger effect (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Effect on HDL'",
"    </a>",
"    below). Triglyceride concentrations fall by an average of 20 to 40 percent depending upon the statin and dose used (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Effect on triglycerides'",
"    </a>",
"    below). The reduction in plasma triglycerides is due to a decrease in VLDL synthesis and to clearance of VLDL remnant particles by apo",
"    <span class=\"nowrap\">",
"     B/E",
"    </span>",
"    (LDL) receptors.",
"   </p>",
"   <p>",
"    The mechanisms by which statins may affect cardiovascular disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The statins are commonly used in the treatment of hypercholesterolemia and mixed hyperlipidemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Effect on LDL cholesterol",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Potency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The statins are the most powerful drugs for lowering LDL-cholesterol (LDL-C), with reductions in the range of 30 to 63 percent (",
"    <a class=\"graphic graphic_table graphicRef53730 \" href=\"mobipreview.htm?14/30/14829\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. When switching between statin drugs, equipotent doses with regard to LDL-C reduction can be found in the figure (",
"    <a class=\"graphic graphic_figure graphicRef60663 \" href=\"mobipreview.htm?6/34/6703\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     Rosuvastatin",
"    </a>",
"    is somewhat more potent than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/10,11\">",
"     10,11",
"    </a>",
"    ], and both these agents are significantly more potent than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. At maximal prescribed doses, LDL-C reduction is greater with rosuvastatin and atorvastatin than with the other available statins (",
"    <a class=\"graphic graphic_figure graphicRef60663 \" href=\"mobipreview.htm?6/34/6703\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    At doses of up to 40",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    is the least potent statin (",
"    <a class=\"graphic graphic_figure graphicRef60663 \" href=\"mobipreview.htm?6/34/6703\">",
"     figure 2",
"    </a>",
"    ). However, at doses of 80",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    fluvastatin is as effective on lowering LDL-C as most statins other than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/13\">",
"     13",
"    </a>",
"    ]. Fluvastatin is less likely to have drug interactions or produce muscle toxicity than some other statins. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Side effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    80",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    is a moderately-potent dose of statin, given high rates of myopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/14\">",
"     14",
"    </a>",
"    ] and the availability of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    and generic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    , we suggest not treating patients with doses of simvastatin above 40",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Additionally, clinicians should strongly consider switching even patients who are currently tolerating simvastatin 80",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    to one of these other statin options, since future medication therapy or illness could increase the risk for development of myopathy on high-dose simvastatin. High-dose simvastatin may be appropriate for a small number of patients who have tolerated it well for many years or who are intolerant of other high-potency statin options.",
"   </p>",
"   <p>",
"    There is an additive hypolipidemic effect when any of the statins is used in combination with a bile acid sequestrant (",
"    <a class=\"graphic graphic_figure graphicRef63912 \" href=\"mobipreview.htm?40/17/41246\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/15-17\">",
"     15-17",
"    </a>",
"    ], or the cholesterol absorption inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42217?source=see_link&amp;anchor=H9#H9\">",
"     \"Lipid lowering with drugs other than statins and fibrates\", section on 'Ezetimibe'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     LDL subfractions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statins are the most effective agents for lowering total LDL particle concentration, however they are nonselective for reducing LDL subclasses; they reduce the predominant subclass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/18\">",
"     18",
"    </a>",
"    ]. Among patients with the atherogenic dyslipidemia profile, the reduction in the predominant subclass of small, dense LDL particles results in a shift of the LDL subfractions to more buoyant, and potentially less atherogenic, LDL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=see_link&amp;anchor=H22#H22\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\", section on 'Small dense LDL (LDL phenotype B)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18138?source=see_link&amp;anchor=H17#H17\">",
"     \"Lipoprotein classification; metabolism; and role in atherosclerosis\", section on 'Intermediate density lipoprotein (remnant lipoproteins)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18138?source=see_link&amp;anchor=H16#H16\">",
"     \"Lipoprotein classification; metabolism; and role in atherosclerosis\", section on 'Low density lipoprotein'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Effect on HDL",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     Simvastatin",
"    </a>",
"    (40 to 80",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    appears to be more effective than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    (20 to 40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for increasing serum HDL-C and apolipoprotein A-I concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/22\">",
"     22",
"    </a>",
"    ]. However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    may be even more effective, raising HDL-C by up to 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/11\">",
"     11",
"    </a>",
"    ]. In metabolic syndrome patients, rosuvastatin (10 to 20",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    was more effective than atorvastatin (10 to 20",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in increasing large HDL particles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/18\">",
"     18",
"    </a>",
"    ]. Whether this is clinically important is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/2/39978?source=see_link\">",
"     \"HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Effect on triglycerides",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     Atorvastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    are more effective at lowering triglycerides (14 to 33 percent) than other statins in patients with hypercholesterolemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/11,23-25\">",
"     11,23-25",
"    </a>",
"    ]. The magnitude of triglyceride lowering with statins may be larger in patients with hypertriglyceridemia.",
"   </p>",
"   <p>",
"    The effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    on serum triglycerides are dose-dependent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/11,23\">",
"     11,23",
"    </a>",
"    ]. As an example, in a series of 56 patients with primary hypertriglyceridemia in whom the average triglyceride concentration was 600",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and LDL-C concentration was 120",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.1",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    the administration of atorvastatin at doses of 5, 20, or 80",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    produced reductions in triglycerides of 27, 32, and 46 percent, respectively, and in LDL-C of 17, 33, and 41 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Genetic/ethnic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Part of the variability in the response to and side effects with statins may be related to genetic differences in the rate of drug metabolism. As an example, CYP2D6 is a member of the cytochrome P450 superfamily of drug oxidizing enzymes. CYP2D6 is functionally absent in 7 percent of Caucasians and African-Americans, while deficiency is rare among Asians.",
"   </p>",
"   <p>",
"    The CYP2D6 phenotype appears to be important in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    , as it can affect both the degree of lipid lowering and tolerability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/26\">",
"     26",
"    </a>",
"    ]. Polymorphisms in the gene coding for HMG CoA reductase also appear to affect the LDL-C response to statins, but not the HDL-C response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concerns have been raised that Asians may have greater responses to low doses of statins than Caucasians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/28\">",
"     28",
"    </a>",
"    ]. Prescribing information for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    recommends starting therapy at a lower initial dose in Asians than in other groups, given observed differences in pharmacokinetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/29\">",
"     29",
"    </a>",
"    ]. There is no strong evidence supporting such an approach with other statins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prevention of cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major use of statins is in the primary and secondary prevention of cardiovascular disease. This use is discussed extensively elsewhere:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=see_link\">",
"       \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link\">",
"       \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=see_link\">",
"       \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/50/19240?source=see_link\">",
"       \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link\">",
"       \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33656?source=see_link\">",
"       \"Cholesterol lowering after an acute coronary syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=see_link\">",
"       \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse reactions occur less frequently with the statins than with most other classes of lipid lowering agents. Hepatic dysfunction has been a source of concern; however, the actual risk appears to be very small. Myopathy remains an important side effect.",
"   </p>",
"   <p>",
"    There have been concerns that the more lipophilic statins (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    ) may be associated with more adverse events than the more hydrophilic statins (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]; however, fluvastatin (a lipophilic statin) appears to have a low rate of muscle side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In randomized trials, statin therapy appears to cause only a slight increased risk of side effects compared with placebo, and no increased risk of discontinuation of therapy compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. However, experience in clinical practice suggests that muscle side effects are relatively common, including side effects requiring discontinuation of statin therapy. The explanation for this difference is uncertain, but may relate to selection criteria in randomized trials that limit the ability to generalize their results to the side effect profiles seen in a broader population of patients.",
"   </p>",
"   <p>",
"    Observational data suggest that while discontinuation of statin therapy for side effects is relatively common, many of these patients tolerate the same statin or another statin when rechallenged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hepatic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical studies of statins have demonstrated a 0.5 to 3.0 percent occurrence of persistent elevations in aminotransferases in patients receiving statins. This has primarily occurred during the first three months of therapy and is dose-dependent. Rare episodes of more severe liver injury have also been seen, and one study suggested that these predominantly occur three to four months after initiation of statin therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/36\">",
"     36",
"    </a>",
"    ]. However, these are sufficiently uncommon that overall the incidence of hepatic failure in patients taking statins appears to be no different from the incidence in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several randomized trials have reported no significant difference in the incidence of persistently elevated aminotransferases between statin and placebo therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. A similar finding was noted in a review of three",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    trials with over 112,000 patient-years of exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/41\">",
"     41",
"    </a>",
"    ]. There was no difference in the incidence or severity of serum aminotransferase elevations with pravastatin or placebo, including patients with aminotransferase elevations at study entry. A meta-analysis of 35 randomized trials found an excess risk of aminotransferase elevation with statin therapy versus placebo of 4.2 cases per 1000 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A large cohort study from England and Wales found similar risks of hepatic dysfunction with different statins, with the exception of a higher risk with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of one year of records for 1014 patients taking statins in a primary care practice found that 1 percent of patients had transaminase elevations more than three times normal, and 0.5 percent had transaminase elevations two to three times normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/43\">",
"     43",
"    </a>",
"    ]. None of these elevations appeared to be related to statin use. Similarly, a review of five years of a health maintenance organization's computerized records on 23,000 patients who were receiving statins found that 17 (0.1 percent) had an alanine aminotransferase level more than 10 times the upper limit of normal that appeared to be attributable to statin therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/44\">",
"     44",
"    </a>",
"    ]. Of these, all but four were associated with drug interactions.",
"   </p>",
"   <p>",
"    In 2012, the US Food and Drug Administration revised its labeling information on statins to only recommend liver function testing prior to initiation of statin therapy and to only repeat such testing for clinical indications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/45\">",
"     45",
"    </a>",
"    ]. We and others agree that routine monitoring of liver function tests in patients receiving statin therapy is not necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/40,44,46,47\">",
"     40,44,46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend changing medications or lowering the statin dose in patients who are found to have an alanine aminotransferase (ALT) level more than three times the upper limit of normal that is confirmed on a second occasion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Muscle injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Development of muscle toxicity remains a concern with the use of the statins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/30,48,49\">",
"     30,48,49",
"    </a>",
"    ]. Myopathic syndromes associated with statins span a spectrum of complaints ranging from myalgias to myositis to overt rhabdomyolysis, which may be associated with acute renal failure from myoglobinuria. This problem, including predisposing drug interactions, is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33802?source=see_link\">",
"     \"Statin myopathy\"",
"    </a>",
"    .) Summarized briefly:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Muscle injury is uncommon with statin therapy alone, with a frequency of 2 to 11 percent for myalgias, 0.5 percent for myositis, and less than 0.1 percent for rhabdomyolysis.",
"     </li>",
"     <li>",
"      Patients can experience statin-induced myalgias without an elevation in serum creatine kinase (CK) concentration.",
"     </li>",
"     <li>",
"      Muscle symptoms usually begin within weeks to months after starting statins. Myalgias, weakness, and serum CK concentrations usually return to normal over days to weeks after drug discontinuation.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"       Pravastatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"       fluvastatin",
"      </a>",
"      appear to have less intrinsic muscle toxicity.",
"     </li>",
"     <li>",
"      Enhanced susceptibility to statin-associated myopathy occurs in patients with acute or chronic renal failure, obstructive liver disease, and hypothyroidism.",
"     </li>",
"     <li>",
"      If a patient requires a statin and experiences muscle toxicity (other than rhabdomyolysis) with a statin other than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"       fluvastatin",
"      </a>",
"      , once symptoms have resolved off statin therapy, it is reasonable to consider a trial of pravastatin or fluvastatin with careful monitoring.",
"     </li>",
"     <li>",
"      Clinical judgment is necessary in interpreting elevated CK levels in patients on statins. CK elevations can be related to hypothyroidism or trauma during sports (running, diving for a volleyball, hockey), and patients who engage in high-impact sports should be advised to have a CK measured before engaging in exercise that day. In the absence of clinical symptoms, a CK level more than 10 times the upper limit of normal that is felt to be due to a statin is an indication for discontinuing the medication. Patients should drink large quantities of fluids to facilitate renal excretion of myoglobin. After the CK",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      myoglobin have returned to baseline, patients may be tried on a statin less likely to cause muscle toxicity (as above) with careful monitoring.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hypothyroidism is a potential cause of dyslipidemia (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/56/28550?source=see_link\">",
"     \"Lipid abnormalities in thyroid disease\"",
"    </a>",
"    ), and hypothyroidism may predispose patients to statin-induced myopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. As such, we suggest checking a TSH level prior to initiating statin therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Renal dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statins appear to be able to cause proteinuria through tubular inhibition of active transport of small molecular weight proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. There have been a number of reports to the FDA about proteinuria with statins, particularly in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/54\">",
"     54",
"    </a>",
"    ]. However, it is believed that proteinuria with statins is a benign finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30824?source=see_link&amp;anchor=H156847860#H156847860\">",
"     \"Statins and chronic kidney disease\", section on 'Effect on protein excretion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There have also been rare episodes of renal failure in clinical trials of patients treated with 80",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/11\">",
"     11",
"    </a>",
"    ], a higher dose than is available. However, it is unclear if rosuvastatin was responsible for the renal failure, as these patients were on other potentially nephrotoxic medications. Although concerns had been raised about high rates of adverse event reports to the FDA regarding rosuvastatin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/54\">",
"     54",
"    </a>",
"    ], subsequent information suggests that renal adverse events with rosuvastatin are rare and are similar to those seen with other statins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/57-60\">",
"     57-60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Behavioral and cognitive",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although concerns have been raised about increased suicide in patients treated with some lipid lowering therapies, statins do not appear to be associated with an increased risk of suicide or depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Safety of cholesterol lowering'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There have been case reports of patients developing severe irritability and aggression associated with the use of statins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/62\">",
"     62",
"    </a>",
"    ]. It is not known whether the statin use caused these symptoms, but very rare idiosyncratic reactions of this sort could be missed in controlled trials.",
"   </p>",
"   <p>",
"    A retrospective cohort study in elderly patients found an association between perioperative statin use and postoperative delirium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/63\">",
"     63",
"    </a>",
"    ], however it is difficult to tell whether this association was causal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/64\">",
"     64",
"    </a>",
"    ]. Perioperative administration of statins may have important cardiovascular benefits. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40666?source=see_link&amp;anchor=H10#H10\">",
"     \"Perioperative medication management\", section on 'Statins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Concerns have been raised in the media and popular press about cognitive dysfunction and memory loss associated with statin use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. A review of adverse events reported to the US Food and Drug Administration between November 1997 and February 2002 found 60 reports of patients who had memory loss associated with statins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/67\">",
"     67",
"    </a>",
"    ]. Fourteen of 25 patients had improvement when the statin was discontinued, and four had recurrence of memory loss on rechallenge. The statins involved were",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    (36 patients),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    (23 patients), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    (1 patient).",
"   </p>",
"   <p>",
"    Although this analysis of adverse event reports does not show that statins cause memory loss, the apparently high rate of reports with lipophilic statins (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    ) compared with hydrophilic statins (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    ) does suggest a possible biologic effect. Randomized trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    and simvastatin have shown some evidence of minor decrements in cognitive function as measured by neuropsychological testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of more definitive data, it may be appropriate for physicians to determine whether statin therapy was recently initiated in patients who develop new memory loss. If an individual patient appears to have memory loss associated with lipophilic statin therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    ) and has a strong indication for lipid lowering therapy, it would be reasonable to attempt treatment with a more hydrophilic statin (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to the above observations suggesting that statins may produce cognitive impairment, other studies have suggested that statins may have a role in the prevention of dementia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41369?source=see_link&amp;anchor=H16#H16\">",
"     \"Prevention of dementia\", section on 'Statins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preclinical studies found that very high-dose statin therapy increased the risk of liver tumors in rodents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As discussed elsewhere, meta-analyses of randomized trials have shown no effect of statins on cancer incidence or cancer mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10230?source=see_link&amp;anchor=H3#H3\">",
"     \"Statins: Possible noncardiovascular benefits\", section on 'Cancer'",
"    </a>",
"    .) A potential limitation of the meta-analyses is relatively short duration of follow-up. However, ten-year follow-up of the 4S trial and the West of Scotland Coronary Prevention Study (WOSCOPS) and 11-year follow-up of the Heart Protection Study (HPS) showed no increases in cancer deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/75-77\">",
"     75-77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, there is no convincing evidence that statins increase or decrease the risk of cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statins could have effects on glucose metabolism that might influence the development of diabetes mellitus in nondiabetics or affect glycemic control in patients with existing diabetes. Experimental evidence has been conflicting about whether statins as a group improve glucose metabolism or whether some statins show beneficial effects while others show harmful effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/78-83\">",
"     78-83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Previously, some clinical trials of statins had reported conflicting results on the issue of glucose metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/84-87\">",
"     84-87",
"    </a>",
"    ]. However, a 2010 meta-analysis of 13 trials (N = 91,140) found little evidence of heterogeneity among large-scale chronic treatment trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/88\">",
"     88",
"    </a>",
"    ]. For inclusion, trials were required to have more than 1000 patients and a duration of follow-up of more than one year. This meta-analysis found an overall small increased risk for diabetes in patients treated with statins (odds ratio [OR] for incident diabetes 1.09, 95% CI 1.02-1.17). Subgroup analyses found very similar diabetes risks in trials of hydrophilic or lipophilic statins, and no clear differences among individual statins. The results were also similar after the exclusion of the JUPITER trial. Since JUPITER had raised much of the concern about diabetes and statins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/85\">",
"     85",
"    </a>",
"    ], the stability of the result without JUPITER lowers the likelihood that the glucose findings in the meta-analysis were due to chance.",
"   </p>",
"   <p>",
"    A 2011 meta-analysis of five randomized trials (N = 32,752) also found an increased risk of incident diabetes with intensive statin therapy compared with moderate statin therapy (OR 1.12, CI 1.04-1.22) with little or no heterogeneity across trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/89\">",
"     89",
"    </a>",
"    ]. This translates into approximately one additional case of diabetes for every 500 patients treated with intensive rather than moderate statin therapy.",
"   </p>",
"   <p>",
"    It appears likely that statin therapy confers a small increased risk of developing diabetes, and that the risk is slightly greater with intensive statin therapy than moderate statin therapy. As would be expected, given the evidence from clinical trials that statins reduce CV events in patient with diabetes (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\"",
"    </a>",
"    ), both randomized trials and observational studies suggest that the beneficial effects of statins on CV events and mortality outweigh any increased risk conferred by promoting the development of diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/90,91\">",
"     90,91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Cataract",
"      </strong>",
"      &ndash; In preclinical toxicity testing, dogs developed cataracts when given doses of statins much higher than human doses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/92\">",
"       92",
"      </a>",
"      ]. While most large case-control and cohort studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/93-95\">",
"       93-95",
"      </a>",
"      ], as well as a small randomized trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/96\">",
"       96",
"      </a>",
"      ], have not found an increased risk of cataract, a large cohort study from England and Wales did find that statin use was associated with an increased risk of cataract [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/42\">",
"       42",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In a subset analysis, one cohort study reported an association between statins and a decreased risk of one type of cataract (nuclear cataract) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/95\">",
"       95",
"      </a>",
"      ]; however, additional study is clearly needed before it can be concluded that statins actually have any such protective effect.",
"     </li>",
"     <li>",
"      <strong>",
"       Neuropathy",
"      </strong>",
"      &ndash; A number of case reports have suggested that statin use may be associated with the development of peripheral neuropathy. In a case-control study that included 166 patients with a first time diagnosis of idiopathic polyneuropathy (35 definite, 54 probable, and 77 possible), the odds ratio of developing polyneuropathy with statin use was 3.7 for all cases (95% CI 1.8-7.6) and 14.2 for definite cases (95% CI 5.3-38) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/97\">",
"       97",
"      </a>",
"      ]. The odds ratio increased with a duration of use of two or more years. For patients ages 50 and older, there was one excess case of idiopathic polyneuropathy for every 2200 person-years of statin use.",
"      <br/>",
"      <br/>",
"      A subsequent case-control study using a computer database to identify 272 patients with idiopathic polyneuropathy based on diagnosis codes did not confirm a significantly increased risk with statin use, however there may have been problems with misclassification and the confidence intervals were wide (odds ratio 1.30, 95% CI 0.3-2.1) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/98\">",
"       98",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      As such, a causal association between statin use and neuropathy remains possible but has not been proven.",
"     </li>",
"     <li>",
"      <strong>",
"       Lupus",
"      </strong>",
"      &ndash; There have been case reports of drug-induced lupus in patients receiving statins. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28168?source=see_link\">",
"       \"Drug-induced lupus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Androgen synthesis",
"      </strong>",
"      &ndash; Some [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/99,100\">",
"       99,100",
"      </a>",
"      ], but not all [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/101\">",
"       101",
"      </a>",
"      ], studies suggest that statins may lower androgen levels in men, although it appears unlikely that this effect is clinically significant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/102\">",
"       102",
"      </a>",
"      ]. Statins may also reduce androgen levels in women, including in women with androgen excess [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Risks in pregnancy and breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, statins are rated category X in pregnancy (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 4",
"    </a>",
"    ), and the recommendation is to",
"    <strong>",
"     discontinue",
"    </strong>",
"    their use",
"    <strong>",
"     prior to conception",
"    </strong>",
"    if possible.",
"   </p>",
"   <p>",
"    Animal studies indicate that at maternally toxic doses statins are associated with adverse fetal outcomes, but limited human data suggest that statins are not major human teratogens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/103\">",
"     103",
"    </a>",
"    ]. Although some authors have recommended that pregnant women can be reassured that the fetal risk is low if inadvertent exposure occurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/103\">",
"     103",
"    </a>",
"    ], an analysis of an FDA surveillance database suggests a possible increase in congenital central nervous system and limb abnormalities with exposure to lipophilic statins during the first trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of statins in pregnancy remains uncertain, however it appears that if statins are in fact harmful, the effect is likely relatively small [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/105-107\">",
"     105-107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data on statin safety in breastfeeding are very limited. In the absence of adequate safety data, use of statins by breastfeeding mothers is discouraged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     ADMINISTRATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Timing of administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of cholesterol synthesis appears to occur at night [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/108\">",
"     108",
"    </a>",
"    ], presumably reflecting the effects of a fasting state. For this reason, it is typically recommended that the statins with shorter half-lives be administered in the evening or at bedtime (",
"    <a class=\"graphic graphic_table graphicRef53730 \" href=\"mobipreview.htm?14/30/14829\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In support of this, trials have found greater reductions in total and LDL cholesterol when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    , which has a relatively short half-life, is administered in the evening rather than in the morning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/109,110\">",
"     109,110",
"    </a>",
"    ]. A small study of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    , which has a long half-life, found no significant differences whether it was administered in the morning or the evening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While it is unknown whether the timing of statin administration is important for clinical outcomes, we typically administer statins at the time recommended by the manufacturer (",
"    <a class=\"graphic graphic_table graphicRef53730 \" href=\"mobipreview.htm?14/30/14829\">",
"     table 3",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"     Lovastatin",
"    </a>",
"    absorption is increased by food, and it should be administered with the morning and evening meals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Alternative dosing regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Every other day statin therapy has been suggested as a strategy to improve utilization and decrease cost. Small studies have compared daily statin use with alternate day dosing, and measured effects on lipid parameters and, in some cases, attainment of cholesterol goals over six to twelve weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/112-116\">",
"     112-116",
"    </a>",
"    ]. Every other day regimens, and even once weekly regimens, have also been evaluated as strategies for improving tolerability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/117-119\">",
"     117-119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Results with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    suggest that to yield similar LDL-C lowering, the every other day dose needs to be on average nearly twice that of the daily dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/112,113,115,119\">",
"     112,113,115,119",
"    </a>",
"    ]. There are few data on alternate day regimens using a dose greater than 40 mg or on how patient adherence is impacted.",
"   </p>",
"   <p>",
"    Major outcomes trials of statins have used daily statin therapy. In the absence of data from large randomized trials demonstrating equivalent effects on clinical outcomes with alternative dosing regimens, we suggest daily dosing in patients who are treated with statins. We prefer other measures for cost control, such as price comparison among generic statins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/120\">",
"     120",
"    </a>",
"    ]. Clinical experience suggests that alternate day dosing may improve the tolerability of statins in patients experiencing myalgias, and this strategy can reasonably be tried in patients unable to tolerate daily statin therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Interchange",
"    </span>",
"    &nbsp;&mdash;&nbsp;When switching between statin drugs, equipotent doses with regard to LDL-C reduction can be found in the figure (",
"    <a class=\"graphic graphic_figure graphicRef60663 \" href=\"mobipreview.htm?6/34/6703\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Potency'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     Simvastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    may be associated with more adverse events than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Side effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug interactions, including with other lipid-lowering agents, can predispose to statin-induced muscle injury. These are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33802?source=see_link\">",
"     \"Statin myopathy\"",
"    </a>",
"    .) Summarized briefly:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk is substantially increased for most statins extensively metabolized by cytochrome P-450 3A4 (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42312?source=see_link\">",
"       lovastatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      and to a lesser extent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      ) with concurrent therapy with drugs that interfere with CYP3A4 (",
"      <a class=\"graphic graphic_table graphicRef76992 \" href=\"mobipreview.htm?9/45/9950\">",
"       table 5",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"       Pravastatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"       fluvastatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"       rosuvastatin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/56/9095?source=see_link\">",
"       pitavastatin",
"      </a>",
"      are preferred when concurrent therapy with a strong inhibitor of CYP3A4 cannot be avoided. Grapefruit juice inhibits CYP3A4, however daily consumption of eight ounces or less of grapefruit juice, or one half of a grapefruit or less, is unlikely to increase the risk of an adverse interaction or muscle injury. (See individual drug monographs for more detailed information on interactions).",
"     </li>",
"     <li>",
"      Despite not being significantly metabolized by CYP3A4,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"       rosuvastatin",
"      </a>",
"      levels are increased by the protease inhibitor combinations",
"      <span class=\"nowrap\">",
"       lopinavir/",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"        ritonavir",
"       </a>",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"        atazanavir",
"       </a>",
"       /ritonavir",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/121\">",
"       121",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"       Pravastatin",
"      </a>",
"      is the statin of choice in patients on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"       Pravastatin",
"      </a>",
"      or perhaps",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"       fluvastatin",
"      </a>",
"      is the statin of choice in patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"       gemfibrozil",
"      </a>",
"      (or other fibric acid derivatives). However, it should be used cautiously and only if the benefit is likely to outweigh the low risk of muscle toxicity.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"       Fenofibrate",
"      </a>",
"      is the preferred fibrate in patients who require combined therapy with a statin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The antiplatelet agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    is a prodrug that is activated via metabolism by CYP3A4. Based on current evidence clopidogrel therapy need not affect the choice of statin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/34/37418?source=see_link&amp;anchor=H29#H29\">",
"     \"Nonresponse and resistance to clopidogrel\", section on 'Statins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine monitoring of serum creatine kinase (CK) levels is not recommended in patients on statins, but it is useful to obtain a baseline CK level for reference purposes prior to starting statin therapy. Patients treated with statins should be alerted to report the new onset of myalgias or weakness. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33802?source=see_link&amp;anchor=H16#H16\">",
"     \"Statin myopathy\", section on 'Monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We check baseline aminotransferase levels prior to initiating statin therapy; we do not routinely monitor these levels in patients on statins. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Hepatic dysfunction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Monitoring of the lipid response to statin therapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\", section on 'Side effects and monitoring'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link&amp;anchor=H28#H28\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Monitoring therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Specific populations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic kidney disease presents an additional challenge for the selection of a statin.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     Atorvastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    do not require dose adjustment and are the statins of choice in patients with severe renal impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/122,123\">",
"     122,123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dose adjustment is warranted with other statins in patients with severe kidney disease (CrCl less than 30",
"    <span class=\"nowrap\">",
"     mL/min).",
"    </span>",
"    If statins other than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    are used,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    may be safer than other statins. As an example, in a subset analysis of 1711 participants with chronic kidney disease (creatinine clearance &le;75",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    from the CARE trial, treatment with pravastatin for a median of 58.9 months significantly improved outcomes compared with placebo without an increase in side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/124\">",
"     124",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Chronic liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with chronic liver disease who require a statin because of high cardiovascular risk, we suggest complete abstinence from alcohol and the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    at a low dose. If the LDL-C remains elevated, combined therapy with a bile acid sequestrant may allow such patients to achieve their LDL-C target. Statins are contraindicated in patients with progressive liver disease.",
"   </p>",
"   <p>",
"    Patients who simply have baseline elevations in aminotransferases do not appear to be at increased risk when prescribed a statin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/37\">",
"     37",
"    </a>",
"    ]. A study that looked at patients without evidence of alcohol abuse, hepatitis B, or hepatitis C compared a cohort of 342 patients (many of whom presumably had fatty liver or nonalcoholic steatohepatitis) with hyperlipidemia and baseline aminotransferase elevation (AST &gt;40",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    [mean 55",
"    <span class=\"nowrap\">",
"     IU/L]",
"    </span>",
"    or ALT &gt;35",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    [mean 43",
"    <span class=\"nowrap\">",
"     IU/L])",
"    </span>",
"    who were prescribed a statin with a cohort of 2245 patients with baseline aminotransferase elevation who were not prescribed a statin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/125\">",
"     125",
"    </a>",
"    ]. There was no significant difference between the cohorts in the incidence of mild to moderate aminotransferase elevations (4.7 versus 6.4 percent) or severe elevations (0.6 versus 0.4 percent). Rates of aminotransferase elevations were also similar in a cohort of hyperlipidemic patients with and without hepatitis C who were prescribed a statin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 36-week randomized trial comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    80 mg daily or placebo in 326 patients with well-compensated noncholestatic chronic liver disease (64 percent with nonalcoholic steatohepatitis; 23 percent with hepatitis C) found similar evidence of safety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/127\">",
"     127",
"    </a>",
"    ]. Over the course of the trial, rates of aminotransferase elevations were low in the group receiving pravastatin and no different from placebo, and none of the patients had an exacerbation of their underlying liver disease. Similarly, a post-hoc analysis of a randomized trial of statin therapy (mainly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    , 24 mg daily) found no evidence of increased hepatic risk in patients with moderately abnormal liver function tests at baseline who were treated with a statin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a small study of patients with primary biliary cirrhosis who were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    , significant transaminase elevations were common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/129\">",
"     129",
"    </a>",
"    ]. Most statins are ultimately excreted in the bile, and toxic levels can develop in patients with cholestasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/130\">",
"     130",
"    </a>",
"    ]. Additionally, the standard calculation of LDL-C does not exclude lipoprotein X, which can accumulate in cholestasis but is not atherogenic and so not a target of therapy. While it may be possible to use statins safely in patients with mild cholestasis who have an appropriate indication for therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/35/32314/abstract/131\">",
"     131",
"    </a>",
"    ], we avoid statin therapy in patients with significant cholestasis unless there are compelling indications such as established atherosclerotic vascular disease that is considered clinically important. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18149?source=see_link&amp;anchor=H3#H3\">",
"     \"Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis\", section on 'Cholesterol profile'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18149?source=see_link&amp;anchor=H6#H6\">",
"     \"Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis\", section on 'Drug therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of statins is believed to be safe in patients with Gilbert&rsquo;s syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42359?source=see_link\">",
"     \"Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1938739998\">",
"    <span class=\"h1\">",
"     STATIN INTOLERANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, while data from clinical trials suggest low rates of statin side effects leading to discontinuation, in clinical experience it is relatively common to find patients who are intolerant of one or more statins because of myalgias or other muscular symptoms (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Side effects'",
"    </a>",
"    above). Less commonly, aminotransferase elevations require making changes in the statin, the statin dosage, or changes to another class of cholesterol-lowering therapy.",
"   </p>",
"   <p>",
"    Options for managing",
"    <strong>",
"     statin-induced muscle injury",
"    </strong>",
"    are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33802?source=see_link&amp;anchor=H21#H21\">",
"     \"Statin myopathy\", section on 'Prevention and management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Options in patients with",
"    <strong>",
"     aminotransferase elevations",
"    </strong>",
"    (more than three times the upper limit of normal; confirmed on repeat testing) are similar, and include (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Hepatic dysfunction'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Use of a different statin (particularly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Dose reduction",
"     </li>",
"     <li>",
"      Alternate day therapy (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Alternative dosing regimens'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these measures, many patients do not tolerate statin therapy. The clinical management of patients unable to take statin therapy for primary or secondary prevention is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=see_link&amp;anchor=H1938740108#H1938740108\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\", section on 'Statin intolerance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link&amp;anchor=H21#H21\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Drug therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=see_link\">",
"       \"Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statins are the most powerful drugs available for lowering LDL-C and are the most effective lipid lowering drugs for improving clinical outcomes when used for primary and secondary prevention of cardiovascular disease. The choice of statin depends upon a number of factors, including the degree of hyperlipidemia, pharmacokinetic properties, drug interactions, the presence of renal impairment, and cost.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"       Rosuvastatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      cause the greatest percentage change in LDL-C; they are preferred in patients who require a potent statin because of high cardiovascular risk or who require &gt;35 percent reduction in LDL-C. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Potency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with severe renal impairment, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"       fluvastatin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). These medications do not require dose adjustment. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Chronic kidney disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with chronic liver disease who require a statin because of high cardiovascular risk, we suggest complete abstinence from alcohol and the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      at a low dose (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Chronic liver disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fewer pharmacokinetic drug interactions are likely to occur with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"       fluvastatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"       rosuvastatin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/56/9095?source=see_link\">",
"       pitavastatin",
"      </a>",
"      because they are not metabolized through the CYP3A4 (",
"      <a class=\"graphic graphic_table graphicRef76992 \" href=\"mobipreview.htm?9/45/9950\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no clear data that the adverse event profile differs significantly among statins. However,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"       fluvastatin",
"      </a>",
"      appear less likely to cause muscle toxicity than other statins. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33802?source=see_link\">",
"       \"Statin myopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest not routinely monitoring serum creatine kinase (CK), but it is useful to obtain a baseline CK level for reference purposes prior to starting statin therapy. Patients treated with statins should be alerted to report the new onset of myalgias or weakness. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33802?source=see_link&amp;anchor=H16#H16\">",
"       \"Statin myopathy\", section on 'Monitoring'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest checking baseline aminotransferase levels prior to initiating statin therapy; routine monitoring of these levels is not necessary for patients on statins. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Hepatic dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest checking a TSH level prior to initiating statin therapy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Muscle injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapeutic decision making in patients with elevated lipid levels, including indications for and dosing of statins, is discussed in detail separately:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=see_link\">",
"       \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link\">",
"       \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=see_link\">",
"       \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/1\">",
"      Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001; 292:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/2\">",
"      Ness GC, Zhao Z, Lopez D. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation. Arch Biochem Biophys 1996; 325:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/3\">",
"      Conde K, Vergara-Jimenez M, Krause BR, et al. Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig. J Lipid Res 1996; 37:2372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/4\">",
"      Arad Y, Ramakrishnan R, Ginsberg HN. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. J Lipid Res 1990; 31:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/5\">",
"      Ness GC, Chambers CM, Lopez D. Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity. J Lipid Res 1998; 39:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/6\">",
"      Larsen ML, Illingworth DR. Drug treatment of dyslipoproteinemia. Med Clin North Am 1994; 78:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/7\">",
"      Levy RI, Troendle AJ, Fattu JM. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation 1993; 87:III45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/8\">",
"      Illingworth DR, Stein EA, Mitchel YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med 1994; 154:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/9\">",
"      Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/10\">",
"      Rosenson RS. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther 2003; 1:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/11\">",
"      Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/12\">",
"      Brown AS, Bakker-Arkema RG, Yellen L, et al. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol 1998; 32:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/13\">",
"      Eidelman RS, Lamas GA, Hennekens CH. The new National Cholesterol Education Program guidelines: clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease. Arch Intern Med 2002; 162:2033.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/Drugs/DrugSafety/ucm256581.htm (Accessed on March 15, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/15\">",
"      Sprecher DL, Abrams J, Allen JW, et al. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med 1994; 120:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/16\">",
"      Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/17\">",
"      Pan HY, DeVault AR, Swites BJ, et al. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Ther 1990; 48:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/18\">",
"      Rosenson RS, Otvos JD, Hsia J. Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. Diabetes Care 2009; 32:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/19\">",
"      M&auml;rz W, Scharnagl H, Abletshauser C, et al. Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype. Circulation 2001; 103:1942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/20\">",
"      Otvos JD, Shalaurova I, Freedman DS, Rosenson RS. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis 2002; 160:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/21\">",
"      Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/22\">",
"      Kastelein JJ, Isaacsohn JL, Ose L, et al. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol 2000; 86:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/23\">",
"      Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996; 275:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/24\">",
"      Davidson M, McKenney J, Stein E, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol 1997; 79:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/25\">",
"      Dart A, Jerums G, Nicholson G, et al. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997; 80:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/26\">",
"      Mulder AB, van Lijf HJ, Bon MA, et al. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin Pharmacol Ther 2001; 70:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/27\">",
"      Chasman DI, Posada D, Subrahmanyan L, et al. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004; 291:2821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/28\">",
"      Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol 2007; 99:410.",
"     </a>",
"    </li>",
"    <li>",
"     www.astrazeneca-us.com/pi/crestor.pdf (Accessed on February 08, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/30\">",
"      Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004; 116:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/31\">",
"      Brewer HB Jr. Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. Am J Cardiol 2003; 92:23K.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/32\">",
"      Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther 2005; 19:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/33\">",
"      Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006; 114:2788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/34\">",
"      Armitage J. The safety of statins in clinical practice. Lancet 2007; 370:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/35\">",
"      Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med 2013; 158:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/36\">",
"      Bj&ouml;rnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol 2012; 56:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/37\">",
"      Cohen DE, Anania FA, Chalasani N, National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardiol 2006; 97:77C.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/38\">",
"      Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/39\">",
"      Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/40\">",
"      Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/41\">",
"      Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 2002; 105:2341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/42\">",
"      Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010; 340:c2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/43\">",
"      Smith CC, Bernstein LI, Davis RB, et al. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. Arch Intern Med 2003; 163:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/44\">",
"      Charles EC, Olson KL, Sandhoff BG, et al. Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med 2005; 118:618.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/ucm293101.htm (Accessed on February 28, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/46\">",
"      Weismantel D, Danis P. Clinical inquiries. What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterol-lowering agents? J Fam Pract 2001; 50:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/47\">",
"      Gotto AM Jr. Safety and statin therapy: reconsidering the risks and benefits. Arch Intern Med 2003; 163:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/48\">",
"      Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003; 163:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/49\">",
"      Thompson PD, Clarkson PM, Rosenson RS, National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel. An assessment of statin safety by muscle experts. Am J Cardiol 2006; 97:69C.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/50\">",
"      Bar SL, Holmes DT, Frohlich J. Asymptomatic hypothyroidism and statin-induced myopathy. Can Fam Physician 2007; 53:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/51\">",
"      Lando HM, Burman KD. Two cases of statin-induced myopathy caused by induced hypothyroidism. Endocr Pract 2008; 14:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/52\">",
"      Vidt DG, Cressman MD, Harris S, et al. Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004; 102:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/53\">",
"      Sidaway JE, Davidson RG, McTaggart F, et al. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J Am Soc Nephrol 2004; 15:2258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/54\">",
"      Alsheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 2005; 111:3051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/55\">",
"      Grundy SM. The issue of statin safety: where do we stand? Circulation 2005; 111:3016.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/cder/drug/infopage/rosuvastatin/crestor_CP.pdf (Accessed on June 10, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/57\">",
"      McAfee AT, Ming EE, Seeger JD, et al. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy. Pharmacoepidemiol Drug Saf 2006; 15:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/58\">",
"      Guthrie RM, Martin DR. The safety of rosuvastatin: effects on renal and hepatic function. Expert Opin Drug Saf 2007; 6:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/59\">",
"      Garc&iacute;a-Rodr&iacute;guez LA, Mass&oacute;-Gonz&aacute;lez EL, Wallander MA, Johansson S. The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care. Pharmacoepidemiol Drug Saf 2008; 17:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/60\">",
"      Garc&iacute;a-Rodr&iacute;guez LA, Gonz&aacute;lez-P&eacute;rez A, Stang MR, et al. The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases. Pharmacoepidemiol Drug Saf 2008; 17:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/61\">",
"      Yang CC, Jick SS, Jick H. Lipid-lowering drugs and the risk of depression and suicidal behavior. Arch Intern Med 2003; 163:1926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/62\">",
"      Golomb BA, Kane T, Dimsdale JE. Severe irritability associated with statin cholesterol-lowering drugs. QJM 2004; 97:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/63\">",
"      Redelmeier DA, Thiruchelvam D, Daneman N. Delirium after elective surgery among elderly patients taking statins. CMAJ 2008; 179:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/64\">",
"      Marcantonio ER. Statins and postoperative delirium. CMAJ 2008; 179:627.",
"     </a>",
"    </li>",
"    <li>",
"     CGS News www.cbsnews.com/stories/2004/05/24/eveningnews/main619351.shtml (Accessed on March 07, 2005).",
"    </li>",
"    <li>",
"     Graveline D. Lipitor: Thief of memory: Statin Drugs and the Misguided War on Cholesterol, Infinity Publishing, Haverford, PA 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/67\">",
"      Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003; 23:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/68\">",
"      Muldoon MF, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med 2000; 108:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/69\">",
"      Muldoon MF, Ryan CM, Sereika SM, et al. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med 2004; 117:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/70\">",
"      Rojas-Fernandez CH, Cameron JC. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother 2012; 46:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/71\">",
"      Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996; 275:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/72\">",
"      Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/73\">",
"      Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a meta-analysis. JAMA 2006; 295:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/74\">",
"      Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2007; 120:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/75\">",
"      Strandberg TE, Py&ouml;r&auml;l&auml; K, Cook TJ, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004; 364:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/76\">",
"      Ford I, Murray H, Packard CJ, et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007; 357:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/77\">",
"      Heart Protection Study Collaborative Group, Bulbulia R, Bowman L, et al. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet 2011; 378:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/78\">",
"      Yu Y, Ohmori K, Chen Y, et al. Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model. J Am Coll Cardiol 2004; 44:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/79\">",
"      Wong V, Stavar L, Szeto L, et al. Atorvastatin induces insulin sensitization in Zucker lean and fatty rats. Atherosclerosis 2006; 184:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/80\">",
"      Chen Y, Ohmori K, Mizukawa M, et al. Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes. Circ J 2007; 71:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/81\">",
"      Mita T, Watada H, Nakayama S, et al. Preferable effect of pravastatin compared to atorvastatin on beta cell function in Japanese early-state type 2 diabetes with hypercholesterolemia. Endocr J 2007; 54:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/82\">",
"      Yamakawa T, Takano T, Tanaka S, et al. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2008; 15:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/83\">",
"      Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL. The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. J Clin Endocrinol Metab 2009; 94:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/84\">",
"      Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/85\">",
"      Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195.",
"     </a>",
"    </li>",
"    <li>",
"     Shepherd J. Glasgow Royal Infirmary, 2008, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/87\">",
"      Coleman CI, Reinhart K, Kluger J, White CM. The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2008; 24:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/88\">",
"      Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/89\">",
"      Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011; 305:2556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/90\">",
"      Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012; 380:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/91\">",
"      Wang KL, Liu CJ, Chao TF, et al. Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/92\">",
"      Gerson RJ, MacDonald JS, Alberts AW, et al. On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors. Exp Eye Res 1990; 50:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/93\">",
"      Schlienger RG, Haefeli WE, Jick H, Meier CR. Risk of cataract in patients treated with statins. Arch Intern Med 2001; 161:2021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/94\">",
"      Smeeth L, Hubbard R, Fletcher AE. Cataract and the use of statins: a case-control study. QJM 2003; 96:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/95\">",
"      Klein BE, Klein R, Lee KE, Grady LM. Statin use and incident nuclear cataract. JAMA 2006; 295:2752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/96\">",
"      Harris ML, Bron AJ, Brown NA, et al. Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group. Br J Ophthalmol 1995; 79:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/97\">",
"      Gaist D, Jeppesen U, Andersen M, et al. Statins and risk of polyneuropathy: a case-control study. Neurology 2002; 58:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/98\">",
"      Anderson JL, Muhlestein JB, Bair TL, et al. Do statins increase the risk of idiopathic polyneuropathy? Am J Cardiol 2005; 95:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/99\">",
"      Dobs AS, Schrott H, Davidson MH, et al. Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism 2000; 49:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/100\">",
"      Davidson MH, Stein EA, Dujovne CA, et al. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol 1997; 79:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/101\">",
"      Azzarito C, Boiardi L, Vergoni W, et al. Testicular function in hypercholesterolemic male patients during prolonged simvastatin treatment. Horm Metab Res 1996; 28:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/102\">",
"      Santini SA, Carrozza C, Lulli P, et al. Atorvastatin treatment does not affect gonadal and adrenal hormones in type 2 diabetes patients with mild to moderate hypercholesterolemia. J Atheroscler Thromb 2003; 10:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/103\">",
"      Hosokawa A, Bar-Oz B, Ito S. Use of lipid-lowering agents (statins) during pregnancy. Can Fam Physician 2003; 49:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/104\">",
"      Edison RJ, Muenke M. Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N Engl J Med 2004; 350:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/105\">",
"      Kazmin A, Garcia-Bournissen F, Koren G. Risks of statin use during pregnancy: a systematic review. J Obstet Gynaecol Can 2007; 29:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/106\">",
"      Taguchi N, Rubin ET, Hosokawa A, et al. Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod Toxicol 2008; 26:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/107\">",
"      Costantine MM, Cleary K, Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric--Fetal Pharmacology Research Units Network. Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstet Gynecol 2013; 121:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/108\">",
"      Miettinen TA. Diurnal variation of cholesterol precursors squalene and methyl sterols in human plasma lipoproteins. J Lipid Res 1982; 23:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/109\">",
"      Saito Y, Yoshida S, Nakaya N, et al. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study. Arterioscler Thromb 1991; 11:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/110\">",
"      Wallace A, Chinn D, Rubin G. Taking simvastatin in the morning compared with in the evening: randomised controlled trial. BMJ 2003; 327:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/111\">",
"      Cilla DD Jr, Gibson DM, Whitfield LR, Sedman AJ. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol 1996; 36:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/112\">",
"      Rindone JP, Hiller D, Arriola G. A comparison of fluvastatin 40 mg every other day versus 20 mg every day in patients with hypercholesterolemia. Pharmacotherapy 1998; 18:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/113\">",
"      Matalka MS, Ravnan MC, Deedwania PC. Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS). Am Heart J 2002; 144:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/114\">",
"      Jafari M, Ebrahimi R, Ahmadi-Kashani M, et al. Efficacy of alternate-day dosing versus daily dosing of atorvastatin. J Cardiovasc Pharmacol Ther 2003; 8:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/115\">",
"      Ferrer-Garc&iacute;a JC, P&eacute;rez-Silvestre J, Mart&iacute;nez-Mir I, Herrera-Ballester A. Alternate-day dosing of atorvastatin: effects in treating type 2 diabetic patients with dyslipidaemia. Acta Diabetol 2006; 43:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/116\">",
"      Wongwiwatthananukit S, Sansanayudh N, Dhummauppakorn R, Kitiyadisai C. Efficacy and safety of rosuvastatin every other day compared with once daily in patients with hypercholesterolemia. Ann Pharmacother 2006; 40:1917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/117\">",
"      Backes JM, Venero CV, Gibson CA, et al. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother 2008; 42:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/118\">",
"      Kayik&ccedil;io��lu M, Ozerkan F, Soydan I. Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia. Am J Cardiol 1999; 83:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/119\">",
"      Ruisinger JF, Backes JM, Gibson CA, Moriarty PM. Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance. Am J Cardiol 2009; 103:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/120\">",
"      Drugs for lipids. Treat Guidel Med Lett 2008; 6:9.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/Safety/MedWatch/SafetyInformation/ucm200635.htm (Accessed on February 19, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/122\">",
"      Chong PH, Seeger JD, Franklin C. Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med 2001; 111:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/123\">",
"      Kasiske BL, Wanner C, O'Neill WC, National Lipid Association Statin Safety Task Force Kidney Expert Panel. An assessment of statin safety by nephrologists. Am J Cardiol 2006; 97:82C.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/124\">",
"      Tonelli M, Moy&eacute; L, Sacks FM, et al. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003; 138:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/125\">",
"      Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004; 126:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/126\">",
"      Khorashadi S, Hasson NK, Cheung RC. Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol 2006; 4:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/127\">",
"      Lewis JH, Mortensen ME, Zweig S, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007; 46:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/128\">",
"      Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/129\">",
"      Stojakovic T, Putz-Bankuti C, Fauler G, et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 2007; 46:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/130\">",
"      Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis 2007; 194:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/35/32314/abstract/131\">",
"      Abu Rajab M, Kaplan MM. Statins in primary biliary cirrhosis: are they safe? Dig Dis Sci 2010; 55:2086.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4564 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-91.202.164.29-5B3EA195B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_35_32314=[""].join("\n");
var outline_f31_35_32314=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Effect on LDL cholesterol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Potency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - LDL subfractions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Effect on HDL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Effect on triglycerides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Genetic/ethnic effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hepatic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Muscle injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Renal dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Behavioral and cognitive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Risks in pregnancy and breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Timing of administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Alternative dosing regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Interchange",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Specific populations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1938739998\">",
"      STATIN INTOLERANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/4564\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4564|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/8/44175\" title=\"figure 1\">",
"      Mechanism of statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/34/6703\" title=\"figure 2\">",
"      Comparison statin drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/17/41246\" title=\"figure 3\">",
"      Effects combined statin resin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4564|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/1/28701\" title=\"table 1\">",
"      Types of lipid altering drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/47/22268\" title=\"table 2\">",
"      Effects of lipid altering drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/30/14829\" title=\"table 3\">",
"      Properties of statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\" title=\"table 4\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/45/9950\" title=\"table 5\">",
"      Inhibitors and inducers of cytochrome P450 3A4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33656?source=related_link\">",
"      Cholesterol lowering after an acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/50/19240?source=related_link\">",
"      Clinical trials of cholesterol lowering for primary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28168?source=related_link\">",
"      Drug-induced lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42359?source=related_link\">",
"      Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/2/39978?source=related_link\">",
"      HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18149?source=related_link\">",
"      Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=related_link\">",
"      Inherited disorders of LDL-cholesterol metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/56/28550?source=related_link\">",
"      Lipid abnormalities in thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/51/28474?source=related_link\">",
"      Lipid lowering with diet or dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42217?source=related_link\">",
"      Lipid lowering with drugs other than statins and fibrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/39/7800?source=related_link\">",
"      Lipid lowering with fibric acid derivatives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18138?source=related_link\">",
"      Lipoprotein classification; metabolism; and role in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/34/37418?source=related_link\">",
"      Nonresponse and resistance to clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=related_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40666?source=related_link\">",
"      Perioperative medication management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41369?source=related_link\">",
"      Prevention of dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30824?source=related_link\">",
"      Statins and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10230?source=related_link\">",
"      Statins: Possible noncardiovascular benefits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_35_32315="Effect of electrical current";
var content_f31_35_32315=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pathophysiologic effects of different intensities of electrical current",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Current intensity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 mA",
"       </td>",
"       <td>",
"        Tingling sensation; almost not perceptible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3-5 mA",
"       </td>",
"       <td>",
"        \"Let-go\" current for an average child",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6-9 mA",
"       </td>",
"       <td>",
"        \"Let-go\" current for an average adult",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16 mA",
"       </td>",
"       <td>",
"        Maximum current a person can grasp and \"let go\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16-20 mA",
"       </td>",
"       <td>",
"        Tetany of skeletal muscles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20-50 mA",
"       </td>",
"       <td>",
"        Paralysis of respiratory muscles; respiratory arrest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50-100 mA",
"       </td>",
"       <td>",
"        Threshold for ventricular fibrillation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;2 A",
"       </td>",
"       <td>",
"        Asystole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15-30 A",
"       </td>",
"       <td>",
"        Common household circuit breakers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        240 A",
"       </td>",
"       <td>",
"        Maximal intensity of household current (U.S.)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Koumbourlis, AC. Electrical injuries. Crit Care Med 2002; 30:S425. Copyright &copy; 2002 American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_35_32315=[""].join("\n");
var outline_f31_35_32315=null;
var title_f31_35_32316="Pathogens following BMT-I";
var content_f31_35_32316=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pathogens likely to cause infections in bone marrow/stem cell transplant recipients not receiving standard prophylaxis-I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Pre-engraftment (&lt;3 weeks)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Bacteria",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       Gram-positive cocci",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Coagulase-negative staphylococci",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Staphylococcus aureus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Viridans streptococci",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Streptococcus pneumoniae",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Enterococcus (including vancomycin-resistant)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       Gram negative bacilli",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Enterobacteriaceae",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       Escherichia coli",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       Enterobacter spp.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       Klebsiella spp.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Pseudomonas aeruginosa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Stenotrophomonas maltophilia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Legionella pneumophilia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       Anaerobes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Clostridium spp.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       C. difficile",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       C. septicum",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Fungi",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       Candida spp.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       C. albicans",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       C. parapsilosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       C. tropicalis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       Aspergillus spp.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       A. fumigatus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       A. flavus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       A. terreus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Viruses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Herpes simplex virus (HSV)-1, -2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       Respiratory viruses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Respiratory syncytial virus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Influenza",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Parainfluenza",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Adenovirus",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_35_32316=[""].join("\n");
var outline_f31_35_32316=null;
var title_f31_35_32317="Voltage effects on K handling";
var content_f31_35_32317=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F77973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F77973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 513px\">",
"   <div class=\"ttl\">",
"    Voltage and potassium secretion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 493px; height: 373px; background-image: url(data:image/gif;base64,R0lGODlh7QF1AdUAAP///4CAgH9/fwAAAAAz/4CZ/0Bm/8DAwMDN/0BAQPDw8BBA/+Dg4FBz/6Cz/yBN/xAQEKCgoHCN/zAwMNDZ/yAgIGBgYLDA/zBZ/5CQkGCA/9DQ0PDz/1BQUODm/5Cm/7CwsD8/P3BwcL+/v5+fny8vL29vb+/v719fXwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADtAXUBAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wMHCw8TFxsfIycrLzM3Oz9DR0sgUCNbWFEcUBg5L291PEgaZHh8FDhxRDgbZTOvtTwYSAO9S8l71St9X++JnHtc8OLnHxN8Sg2L89RvHxwCBhw8ZFkFAoMASihbjEcDkACIBiUocCkFQQCCTAgQQRPkIAKVKJhiFnJsiEonLixWvxKxZBiVE/w1NZsZEwjNJUTAOLO7cyKeaBgIaEFQrCYAkQAISNBi4AMBDAZVereVE0MCAgQ8yHVDIKERk2K5fWyblRqFBg3RVy0pId+6DAQ1463ggsEDlWgAcxGlod24tggcVrVHl4PcsAHF/s90k4kBvOr8NuAJgeZNDAQOhR2pd/NSARaEFLmgVfeFvAbZVIX+1WrUkyg92s/G2OnSd5SKd5XEwjZrr0jMoC3CALNwzvZIfvHZr/RrcTIe1AV8XkhRATcyLe1Nw8FKIB3Gp0WdLiuBvuvLPPWhVfr3c2m5eiaZGdDKl1FJKFD1QAAYEVDNWZDkVoMFpBHRD2ENEiBRTTA9hsP8AAQ8wCNQFBDQgQYmjEYABZEDZ8QFWRXi44AICXVjhh9zc5JAEEiwAgII9PnBgewc2UMADCJwoQQMEcEWagTIy6CAGpy0I4jhPLuAQAR6QSCVknOGYlIEuoeTaAj7e5FJMSjKJ1hAoGYlklA0+ZwaBDiFAookoOvQhReMw+ACWDLHkkAYnNmAeUyLVBOQCQqL0IVscoCnhOI8KeWiii1aVk4auPQWUnyk94OOL4AyY05BDxkTiVw/CahFlDTBokYpGaBjraOPcxBKTt4HJEgcs2UHgEBTASCJauLbFlEvJtihQkgZ8yOoQkAqx3AIYIIbik1J9JGFFTJp0VUbgXpb/kkMCHVWTminddCJJZCKYE6S3FStEtogBOq6snd750YlCAnvkRg7hxdJQxRrKFIMBN8oUtdaiJKAQqLpXlTjW1gSxrhbV5IBWDuNlsYdtHAuvWEpB2DLAHn7w4q0gOevpy7yy6vBtt+Xscx0dSXTuzT+/ay9be14A8WZC6OszS+D6e1t9TI20arou1eTus/XSq1KZXXOo4G2p/iz1bp9WTQZKg2rQbkU8B5wzw4WOozXCjOINQNJLG0gE03zr3SnInSoJqNyDMTgPG8e++KW9UUmZ7AIUAgxikjk5bfPklefs6zgvNqAnUA3XPAdkrpUFAKRkNVh0k2sZiOYFSkd3/wGYTAPgJlmtX/Cb57IvwN4HDrwY1dQlOtlr1yfGBmaGsDt+ML0fXIAmANJDxrLukZU3xO6iozk8e2lDtyrGJY4u98LJr45Va4siEDr3Jna8ke24+42sigh0hj/e8uvTRp4DnqDJbVGuY9yqOOAQDDBJLB8SnhAI9hSAdeQjmTPdeUBUQeCppFgH+1bd8OABJoEILRQQFDj0ZT0CmMNAdYkIBwSVPyJxQAMfeoAHOMCkBSwuXTEEEVcOtgCu+MmDQ2IgiJ43hBZ+QIkOjNeFHpANKD4wJjeMIG6yCCIPBPEBF7BTT84nE8gIcAjFOqID0HQiu13IAOmgAGRqpbcZLv/xfvprIoMqYscHgMkhqEsH4URCARw5jDPNmkYvPMCeNXZLkV84yhVOVDZI5qKQD2kAPCy5BUlaAU2B4aQoR0nKUprylKhMpSpXycpWuvKVsIylLGdJy1ra8pa4zKUud8nLXvryl8AMpjCHSUxVHOAAChCCAiIQgAwks5jQVEUEBjCAAwBAARMYQAIGAIFnRvObo2AABKhpzQMMYAIA2KY1h3CAAICgAx1QQAASEAEAgCAADAAAM70Jzn4mIgEAreY1szmBCligCAHgZjYhMIFxMmCaGQAABCrgz4oOIqHkzAAEGKDOa1pgoufkZ0KtqU0AjFQBDN3AAAJg0Zb+gQH/x0TmNqmZ0ZUCoAM2HcJIAVDSnVpgAD/Np0uH+ocNHDObzpzmBA6QzXrqVKA9FSgIqJkAoloVEB0FgAjGWQGWEmGnUV1nBQbg1Kua9axoTata18pWW7YzAHCNq1znSte62vWueM2rXvfK17769a+ADaxgB0vYvq6zrUuYZ2EXy9jGOvaxkI2sZBebAK8iVglwvSweMqvZJHC2s3T4LGgRatnRxkG0phUCalPbhtWa1rVGeOtkZ0vb2tr2trM97BFgC9pjNiEAIRCAcIdL3OIa97jITa5yl8vc5jr3udCNrnSnS93qJjcEpTUCb1mLWQFwtwoCyG4RfPtdKATAu+WV/0J407uF87I3Cut9LxbcK18nxLe+VaBvZ0kwgivcF79T0K9mg+tf8QL4CQK+LIGt8F8AY1SgiUUvYkdAU5qC18Dyhekx+YmEBK/1BCMYQQlQEOILH5gKHm7rgk18YimkmK0mIEGBW+xiCdO4CA2+cYR1bIQc87jDNv6xj3+s3SDzeMhE/qqRdYzkJKt2yTduspNfTGMpJ5nKLbYykbF8Yi3/mMsH9vIuN3zNAwj1tFCusngZwGFeUrMDADAnhnV65jGAGcA5/qgFQPBLmh7TpgfoAEAjSgQIk+HO+M3xWKlZARFswM0NrcBUWRoAC8yTrIXWrRgQXd8cV5imE8hAnf9rqc1pbpOlCshAB7JJ6U9XVQiyhWwCgmvdWtv61rjOta53zevihqCyc/30pzsQgTbDsqQzZWlDM5ABm2p4ABk4wKNhPdlZ9/ra2M62trfNbeH+mq7CrjCxb1lSc9p0ABU4gAhyKgRD2znNWRZvuEM9alqWFAA/Zek0tcnudE770PDusngXjW5HfzngYRavnvl8ZYTjec3G1jGn5StmiTs80XN2skkv3umMT5njFPd4wzVe8RtP/L0lp/HJ2ZvyFq88vS0/8cvLG/MDz/y7NXcwyFEu8i3vnOU9PzjJg87jm3M35/g1OmuRXl+lp5bp8nW6aaH+XqmPlurstTposZ7/Xq13luvl9bpmwf5dsV+W7Nw1O2LRzlq1t5XtqXU7W+H+2p/DnOgWH7rGPWt3muPd5H3H+d9VHvijD97lhV/64WWe+Kcv3uaNn/rjda73ve828leffNIxv3XNN53W3Q696EdP+m5j1/JHiDVuV8/61rset5pGvexnT/sksLmYDMhAAIqdThHUPg4LF+a+qcrTV//eDQRv9L93yQBuWnMDLL338dswb1Hvstm+L7TxlaD613v/++APv/jlGm6aEjvisExodpFt4dSP//3wj7/8HVv+N5fVlqYeQj5LalTyTv8M1VdvtjRWlSVoxfd/bZB8BudLDIBT6BZR0oeAaRB8/xLIY7dXgRiYgRq4gRzYgR74gSAYgiI4giRYgiZ4giiYgiq4gizYgi74gjAYgzI4gzTYUgpgZjWYVoHWbzloVTQlXswEAgkgAgpgAQnwaPeUT/vUg7+kfkawTRUwVhAAhfoEbRJFUUx4Sw+2Tk5YBNsUZzb1hSg1ASrleVkISRqGTKrFg+k0AGDIUl+Ib0A1AAJ4hrV0AD9lAZr2hXLWhkIwVRFoh7j0aV7ohn0YhwAwVvcniIzYiI74iJAYiXvXffNXiZZ4ia0Xe68FbJjYiZ74iY5VWV1nhpa3XZplihmIioilihXIimzliggIi2qlipQIirZ4i+CniTpFii3lf/+YBXqlF4zCOIzEyFyn51m8uIqc93UZ54uAV3m1J3drRXejJY1qRY2gZY2+xF8z9nva2EsrRgXY2FnfyEvhOAXjaFFbyATliEsURojimIxolYbop1PLKEwgJmIk1l/xeHztqEvnqF7yWHb3SEwx1o3RWJBrN5Bpp5Bvx5Bt55BzB5FxJ5HTSJF1B40A5ow75mTp6E+w+I9W9ZH9FJIWeY0Y6VImqZFJh3ciSVQkCU4r6ZEp2VIzmWQx+U03SWQ5yQu5t3vJNIRMIJQRcIRnsJNCVpPBMHwlFYhHUG74FAUHsIgI5pInmVY9mQvNBwHPF30JkAEJYAHJpAAiEJbTBpX/DMAA7lSWXiVPCdABDKda22deVsmSqYR9RUBNBQVUANBQAdBQ+1dVI2VuCTBO9eSX2fRv8zRefCWKCHaVaJWVuNCFQ1BSCqBNKuV7UwWBgllNfThpKlVZ+cZTn7ZOtUhXjukELzlUknkL+ScEgdluCdCHfRhWtLlS5sSJ5YSHS6WGdGlekHlWrXkLBBgABnhvJTVRO/hotgloNgUBEBABB5ABZbWYAVaXNPlKDchonCmbALAB2VQBTtWcLNWHG+CAkjYEEZB9LoadOKmUFYWURwafIOmePEmfJWmfSely+jmf/Amcdhl1/clk+CmTAxplBfpNHNldAVqKwWlWw2lW/6vpUhF6VRPaUhVqVRdqURlKVBtaUR06VB/qTyGqkg96VSVqkyc6kgm6ViPaTymqjisKky0qSj/Je0LZWjPKmjVqSUxZVU6JBi8KTjGqDFvZlQeoow06THipfW4wpN9UpMlAmd45U24opDtKoT2qSK8JALHZf7oYBlAaTVKaDMV5nHOZBmMKTWWKDNv5gEnKBmtaTG2qk1mKoVt6VnNKTHUaTXs6TH0KTX8qTIFaTIMaTIVKTIcKTIk6TIv6S40qTI/qS5EaTJPaS5UKTMBVjJzaqZ5KesdYe6eJi6RaqrUVppKYqqq6qqzaqq76qrAaq7I6q7Raq7Z6q7iaq7q6q/+82qu++qvAGqy0dKNFYFR1KKyKtAHQmU3Gp6xsiKyQlFC+R01DkE082E7vFE/zVE9JqE8BUI/QqgvOilNOFQAQsG7ZlVAMpVAOBVFXGK6/sIUMUFDjdFAqdU88CFadiUwp9azwegv0iFPINFbt9Gmlpa8mJVB5SIf/Kgx5CAIOpWF5WGcIu1OAmKYNywsK4IATEJcJm65Qta9CoIgZW7Ime7Iom7KsOqqm2rIuG3+oeoqc+LI0W7Pil5ppl6dlp7O4JIvT57NoBbTeyLNaSLRxZ7S1RIs2u7RM+1eoKrRmtaDaBYyfWrVWe7XWFaq7hbSOeqcc2owx23ReC6Jcq6L/S6pxl8pLmdqEYytL3MhgZSujoxWQ8BW38dm2sUS3ULC2rbSOHTlhwsZiJ0aP7Ii3rZSPI1Zi/eiNhvtKevsEfNtLaStKBwm3/ti4ZGq3IIm5bKq5Jcm5dOq5Mgm6fCq6dnq2H4e6I5edjKu6Pue6Qse60URmN3isajC5upRjF9hnAwBnfYhZtssFuJtLeQYBe8a7nglogvaVeRm2WjC8uKRoNKV8kDZRk2ZSlrZN9+dum0a6gCpvwkZvuVRq/IZqqsZqCVthxseyg2VtWPu+8Bu/1zWzcFV/vct7pFZVydaXEMBszvZn0fZv7CtY7iu/BnzAV/ttwVZ/42ZL5UZN/9GXbuiaaWYAvbfkaeFrfYP4aqO5b6dGBEZZBhZsS9LLaAuYd7I7BBT4uikMm+DKeLBbdN5LqKbrpzOMqDUsqDfMqDlsqDsMqT2sqD9MqUHctTGMwu/ZYlILZEdcjQeqZv/5mE2cjU8cb1GsmkOMqUWcflUscFf8W1mstlv8SvJJoLl0T+6kf3C1iPCUTD/pTEawsXCWX12ccLeETdqEvtNUAQT1TDvVhnp5BGVIxwDawrIkrUKwASDQfBWQTM12UCh1UH+oAApAsEfwUS/cYXX8cLfkwQHwaE16mRBgT9ybiAwbWwPgsXHWmJuMcT07TtTETOxGrQllBHhpbrOcXdgDrFiFnMS29EwbsG4JMFVzrFLoVMtEsG6SfIPHdGb+yo6t3HFaSE94aFOsBgLZxGfT9G841VUBoIkqRZWqGc0hd0sHMFNdpUwfdU4M13yWZbC7dcrt2cv3+U0fFbxDEMmELMWGLExj+MLY1E37jMVTTI7kzHNfXLgFfYoHDXQJ/bf1LHMNfXdK7Lz2uNCQh9GU188OqtGb59Gfh8AiPdLFqLWzt8tNm9I1a9Eq29Iu/dIwHdMyPdM0XdM2fdM4ndM6vdM83dM+/dNAHdRCPdREXdRGfdSsFAQAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the electrical events in a typical principal cell in the cortical collecting tubule. Upper panel: Na+ is actively transported from the lumen into the capillary. Cl- follows via the paracellular route after a finite time lag; this delay is responsible for the transepithelial potential difference of -35 to -50 mV, lumen negative. Middle panel: Replacing Na+ in the lumen with the nonreabsorbable cation choline essentially eliminates the potential difference, illustrating the central role of Na+ transport. Lower panel: Replacing Cl- in the lumen with the nonreabsorbable anion SO4(2-) increases the potential difference, thereby favoring the secretion of K+ into the lumen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Giebisch, G, Malnic, G, Klose, RM, Windhager, EE, Am J Physiol 1966; 211:560.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_35_32317=[""].join("\n");
var outline_f31_35_32317=null;
var title_f31_35_32318="Ganglion on wrist";
var content_f31_35_32318=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F65578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F65578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ganglion on the dorsum of the wrist",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 313px; height: 213px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The wrist is a common location for the cystic swelling that is characteristic of ganglia (arrow). Aspiration reveals a clear gelatinous fluid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_35_32318=[""].join("\n");
var outline_f31_35_32318=null;
var title_f31_35_32319="Adrenal hemorrhage CT";
var content_f31_35_32319=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F63935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F63935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Adrenal hemorrhage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 352px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial, noncontrast-enhanced CT scan through the upper abdomen of a 42-year-old woman shows irregular peripheral calcification in a soft tissue mass immediately anterior and superior to the right kidney (arrow). These findings are consistent with chronic hemorrhage of the right adrenal gland.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_35_32319=[""].join("\n");
var outline_f31_35_32319=null;
